10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended June 30, 2006

oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition period from                     to                    

Commission file number 0-19612

ImClone Systems Incorporated

(Exact name of registrant as specified in its charter)

Delaware	04-2834797
(State or other jurisdiction of	(IRS Employer
incorporation or organization)	Identification No.)
180 Varick Street, New York, NY	10014
(Address of principal executive offices)	(Zip Code)

(212) 645-1405

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x     No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer x Accelerated filer o Non-accelerated filer o

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes o    No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Class	Outstanding as of August 1, 2006
Common Stock, par value $.001	(84,217,766) Shares

IMCLONE SYSTEMS INCORPORATED

INDEX

PART I—FINANCIAL INFORMATION
Item 1.	Financial Statements	1
	Unaudited Consolidated Balance Sheets—June 30, 2006 and December 31, 2005	1
	Unaudited Consolidated Statements of Income—Three months and Six months ended June 30, 2006 and 2005	2
	Unaudited Consolidated Statement of Stockholders’ Equity and Comprehensive Income—Six months ended June 30, 2006	3
	Unaudited Consolidated Statements of Cash Flows—Six months ended June 30, 2006 and 2005	4
	Notes to Unaudited Consolidated Financial Statements	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	33
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	50
Item 4.	Controls and Procedures	51
PART II—OTHER INFORMATION
Item 1.	Legal Proceedings	52
Item 1A.	Risk Factors	54
Item 2.	Unregistered Sales of Equity Securities and Uses of Proceeds	55
Item 3.	Defaults upon Senior Securities	55
Item 4.	Submission of Matters to a Vote of Security Holders	55
Item 5.	Other Information	55
Item 6.	Exhibits	55
Signatures		55

i

PART I. FINANCIAL INFORMATION

Item 1.Financial Statements

IMCLONE SYSTEMS INCORPORATED
CONSOLIDATED BALANCE SHEETS
(in thousands, except per share and share data)
(Unaudited)

	June 30, 2006			December 31, 2005
ASSETS
Current assets:
Cash and cash equivalents	$	26,095			$	3,403
Securities available for sale	937,684				752,973
Prepaid expenses	7,549				3,766
Amounts due from corporate partners	90,001				59,271
Inventories (excludes $10,539 at June 30, 2006 classified in Other assets)	66,681				81,394
Deferred income taxes, net	23,316				—
Other current assets	10,167				8,311
Total current assets	1,161,493				909,118
Property, plant and equipment, net	424,533				406,595
Deferred financing costs, net	10,675				12,531
Deferred income taxes, net	106,128				—
Other assets	25,044				15,171
Total assets	$	1,727,873			$	1,343,415
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable (including $2,624 and $4,610 due Bristol-Myers Squibb Company (“BMS”) at June 30, 2006 and December 31, 2005, respectively)	$	32,461			$	35,530
Accrued expenses (including $19,287 and $11,427 due BMS at June 30, 2006 and December 31, 2005, respectively)	76,538				60,934
Withholding tax liability	264				32,000
Current portion of deferred revenue	145,881				112,624
Other current liabilities	1,031				1,031
Total current liabilities	256,175				242,119
Deferred revenue, less current portion	285,285				246,401
Long-term debt	600,000				600,000
Share based compensation	868				—
Deferred rent, less current portion	2,831				2,491
Total liabilities	1,145,159				1,091,011
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $1.00 par value; authorized 4,000,000 shares; reserved 1,200,000 series B participating cumulative preferred stock, none issued or outstanding	—				—
Common stock, $.001 par value; authorized 200,000,000 shares; issued 85,145,933 and 84,412,408 at June 30, 2006 and December 31, 2005, respectively; outstanding 84,141,259 and 83,407,734 at June 30, 2006 and December 31, 2005, respectively	85				84
Additional paid-in capital	798,581				733,069
Accumulated deficit	(175,659		)		(442,459		)
Treasury stock, at cost; 1,004,674 at June 30, 2006 and December 31, 2005, respectively	(29,149		)		(29,149		)
Accumulated other comprehensive loss:
Net unrealized loss on securities available for sale	(11,144		)		(9,141		)
Total stockholders’ equity	582,714				252,404
Total liabilities and stockholders’ equity	$	1,727,873			$	1,343,415

See accompanying notes to consolidated financial statements.

1

IMCLONE SYSTEMS INCORPORATED
CONSOLIDATED STATEMENTS OF INCOME
(in thousands, except per share data)
(Unaudited)

	Three Months Ended June 30						Six Months Ended June 30
	2006			2005			2006			2005
Revenues:
Royalty revenue	$	74,614		$	41,791		$	134,884		$	78,163
License fees and milestone revenue	33,456			24,491			177,859			49,025
Manufacturing revenue	28,356			7,894			47,705			18,913
Collaborative agreement revenue	13,430			18,209			34,539			32,055
Total revenues	149,856			92,385			394,987			178,156
Operating expenses:
Research and development	27,583			24,433			60,576			45,606
Clinical and regulatory	14,929			8,376			30,010			17,774
Marketing, general and administrative	22,963			16,833			40,964			34,456
Royalty expense	18,414			14,338			38,480			26,904
Cost of manufacturing revenue	26,877			1,106			42,279			1,849
Discontinuation of small molecule research program	—			6,200			—			6,200
Total operating expenses	110,766			71,286			212,309			132,789
Operating income	39,090			21,099			182,678			45,367
Other:
Interest income	(10,222		)	(6,793		)	(17,386		)	(13,550		)
Interest expense	1,914			1,687			3,376			3,496
Loss on sales of securities	—			—			—			16
Other, net	(8,308		)	(5,106		)	(14,010		)	(10,038		)
Income before income taxes.	47,398			26,205			196,688			55,405
Provision (benefit) for income taxes	10,189			174			(70,112		)	554
Net income	$	37,209		$	26,031		$	266,800		$	54,851
Income per common share:
Basic	$	0.44		$	0.31		$	3.18		$	0.66
Diluted	$	0.42		$	0.30		$	2.93		$	0.63
Shares used in calculation of income per share
Basic	84,072			83,616			83,849			83,448
Diluted	92,184			92,074			92,001			92,362

See accompanying notes to consolidated financial statements.

2

IMCLONE SYSTEMS INCORPORATED
CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY AND COMPREHENSIVE INCOME
For the Six Months Ended June 30, 2006
(in thousands, except share data)
(Unaudited)

	Preferred Stock					Common Stock				Additional Paid-in			Accumulated				Treasury				Accumulated Other Comprehensive
	Shares		Amount			Shares	Amount			Capital			Deficit				Stock				Loss				Total
Balance at December 31, 2005		—		$	—	84,412,408		$	84		$	733,069		$	(442,459	)		$	(29,149	)		$	(9,141	)	$	252,404
Options exercised						718,470		1			12,592														12,593
Issuance of shares through employee stock purchase plan						15,055		—			460														460
Share based compensation expense											3,965														3,965
Tax benefit of stock options											48,495														48,495
Comprehensive income:
Net income														266,800											266,800
Other comprehensive loss:
Unrealized loss on marketable securities arising during the period																						(2,003		)	(2,003		)
Less: Reclassification adjustment for realized loss included in net income																						—			—
Total other comprehensive loss																						(2,003		)	(2,003		)
Comprehensive income																									264,797
Balance at June 30, 2006		—		$	—	85,145,933		$	85		$	798,581		$	(175,659	)		$	(29,149	)		$	(11,144	)	$	582,714

See accompanying notes to consolidated financial statements.

3

IMCLONE SYSTEMS INCORPORATED
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(Unaudited)

	Six Months Ended June 30,
	2006			2005
Cash flows from operating activities:
Net income	$	266,800		$	54,851
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization	14,573			6,659
Amortization of deferred financing costs	1,856			1,856
Share based compensation	3,965			—
Tax benefit from share based compensation	(48,495		)	—
Loss on disposal of fixed assets	—			3,880
Other	—			82
Deferred income taxes	(129,444		)	—
Changes in:
Prepaid expenses	(3,783		)	(3,670		)
Amounts due from corporate partners	(30,730		)	18,525
Inventories	14,713			(25,794		)
Other current assets	(1,856		)	(827		)
Other assets	(9,934		)	981
Accounts payable	(3,069		)	(2,232		)
Accrued expenses	64,099			(17,358		)
Share based compensation	868			—
Withholding tax liability	(31,736		)	—
Litigation settlement	—			(50,025		)
Deferred rent, less current portion	340			(1,327		)
Deferred revenue	72,141			(50,569		)
Net cash provided by (used in) operating activities	180,308			(64,968		)
Cash flows from investing activities:
Acquisitions of property, plant and equipment	(32,450		)	(52,115		)
Purchases of securities available for sale	(741,409		)	(212,544		)
Proceeds from sale of securities available for sale	546,370			190,309
Maturities of securities available for sale	8,325			52,217
Net cash used in investing activities	(219,164		)	(22,133		)
Cash flows from financing activities:
Proceeds from exercise of stock options	12,593			11,870
Proceeds from issuance of common stock under the employee stock purchase plan	460			498
Tax benefit from share based compensation	48,495			—
Net cash provided by financing activities	61,548			12,368
Net increase (decrease) in cash and cash equivalents	22,692			(74,733		)
Cash and cash equivalents at beginning of period	3,403			79,321
Cash and cash equivalents at end of period	$	26,095		$	4,588
Supplemental cash flow information:
Cash paid for:
Interest, net of amounts capitalized	$	1,519		$	1,639
Income taxes	$	2,408		$	1,400
Non-cash investing and financing activity:
Change in net unrealized loss in securities available-for-sale	$	2,003		$	3,188

See accompanying notes to consolidated financial statements.

4

IMCLONE SYSTEMS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

(1)   Business Overview and Basis of Presentation

The accompanying consolidated financial statements of ImClone Systems Incorporated (“ImClone Systems” or the “Company”) as of June 30, 2006 and for the three and six months ended June 30, 2006 and 2005 are unaudited. The accompanying unaudited consolidated balance sheets, statements of income, statement of stockholders’ equity and comprehensive income and statements of cash flows have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in conjunction with the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the disclosures required by GAAP for complete financial statements. The financial statements reflect all adjustments, consisting only of normal, recurring adjustments, which are in the opinion of management, necessary for a fair presentation for the interim periods. Management of the Company has made a number of estimates and assumptions relating to the reporting of assets and liabilities and related revenue and expense accounts and the disclosure of contingent assets and liabilities to prepare these consolidated financial statements in conformity with GAAP. Actual results could differ materially from those estimates. These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2005, as filed with the SEC.

The results of operations for the interim periods are not necessarily indicative of results to be expected for the entire fiscal year or any other period.

The Company is a biopharmaceutical company whose mission is to advance oncology care by developing and commercializing a portfolio of targeted treatments designed to address the medical needs of patients with cancer. A substantial portion of the Company’s efforts and resources is devoted to research and development conducted on its own behalf and through collaborations with corporate partners and academic research and clinical institutions. The Company does not operate separate lines of business or separate business entities and does not conduct any of its operations outside of the United States. Accordingly, the Company does not prepare discrete financial information with respect to separate product areas or by location and does not have separately reportable segments.

On January 24, 2006, the Company announced that the Board of Directors had engaged the investment bank Lazard to conduct, in conjunction with management, a full review of the Company’s strategic alternatives to maximize shareholder value. These alternatives could include a merger, sale or strategic alliance. There can be no assurances, however, that any particular strategic alternative will be pursued or that any transaction will occur, or on what terms.

On February 12, 2004, the United States Food and Drug Administration (“FDA”) approved ERBITUX® (Cetuximab) Injection for use in combination with irinotecan in the treatment of patients with EGFR-expressing, metastatic colorectal cancer who are refractory to irinotecan-based chemotherapy and for use as a single agent in the treatment of patients with EGFR-expressing, metastatic colorectal cancer who are intolerant to irinotecan-based chemotherapy. In September 2005, Health Canada approved the use of ERBITUX for use in combination with irinotecan for the treatment of EGFR-expressing metastatic colorectal carcinoma in patients who are refractory to other irinotecan-based chemotherapy regimens and for use as a single agent for the treatment of EGFR expressing, metastatic colorectal carcinoma in patients who are intolerant to irinotecan-based chemotherapy. On March 1, 2006, the FDA approved ERBITUX for use in combination with radiation therapy for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (“SCCHN”) and as a single agent in recurrent or metastatic SCCHN where prior platinum-based chemotherapy has failed. Reference full

5

IMCLONE SYSTEMS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(UNAUDITED)

prescribing information, available at www.ERBITUX.com, for important safety information relating to ERBITUX, including boxed warnings.

On December 1, 2003, Swissmedic, the Swiss agency for therapeutic products, approved ERBITUX in Switzerland for the treatment of patients with colorectal cancer who no longer respond to standard chemotherapy treatment with irinotecan. Merck KGaA licensed the right to market ERBITUX outside the United States and Canada from the Company in 1998. In Japan, Merck KGaA has marketing rights to ERBITUX, which are co-exclusive to the co-development rights of the Company and BMS. On June 30, 2004, Merck KGaA received marketing approval by the European Commission to sell ERBITUX for use in combination with irinotecan for the treatment of patients with EGFR-expressing metastatic colorectal cancer after failure of irinotecan including cytotoxic therapy. On December 22, 2005, Swissmedic approved ERBITUX in Switzerland in combination with radiation in the treatment of patients with previously untreated, advanced SCCHN. On April 3, 2006, Merck KGaA was granted marketing authorization by the European Commission to extend the use of ERBITUX, in combination with radiotherapy, to the treatment of patients with locally advanced SCCHN.

Impact of Recent Accounting Pronouncements

In June 2006, the Financial Accounting Standards Board (“FASB”) issued FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes—an interpretation of FASB Statement No. 109. This Interpretation clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements in accordance with FASB No. 109 and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. This Interpretation also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. This Interpretation is effective for fiscal years beginning after December 15, 2006. We are in the process of analyzing the impact that this Interpretation may have on the Company’s consolidated financial statements. Therefore, we are not in a position to conclude whether the adoption of this Interpretation will have a material impact on the Company’s consolidated financial statements.

Comprehensive Income

The following table reconciles net income to comprehensive income: (in thousands)

	Three Months Ended June 30					Six Months Ended June 30
	2006			2005		2006			2005
Net income	$	37,209		$	26,031	$	266,800		$	54,851
Other comprehensive (loss) income:
Unrealized gain (loss) on marketable securities during the period	(670		)	3,896		(2,003		)	(3,188		)
Less: Reclassification adjustment for realized loss included in net income	—			—		—			16
Total other comprehensive (loss) income	(670		)	3,896		(2,003		)	(3,172		)
Total comprehensive income	$	36,539		$	29,927	$	264,797		$	51,679

The tax benefit (expense) on the items included in other comprehensive loss assuming they were recognized in income would be approximately $126,000 and ($60,000) for the three months ended June 30,

6

IMCLONE SYSTEMS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(UNAUDITED)

2006 and 2005, respectively, and $299,000 and $32,000 for the six months ended June 30, 2006 and 2005, respectively.

Fair Value of Financial Instruments

The fair value of the Company’s 13¤8% convertible senior notes of $600,000,000 was approximately $541,500,000 and $502,500,000 at June 30, 2006 and December 31, 2005, respectively, based on their quoted market price.

(2)Inventories

Inventories are stated at the lower of cost, determined on the first-in-first-out method, or market. Inventories consist of the following: (in thousands)

	June 30, 2006		December 31, 2005
Raw materials and supplies	$	19,370		$	22,664
Work in process	48,190			49,149
Finished goods	9,660			9,581
Total	$	77,220		$	81,394

Our policy is to capitalize inventory costs associated with our products when, based on management’s judgment, future economic benefit is expected to be realized. Our accounting policy addresses the attributes that should be considered in evaluating whether the costs to manufacture a product have met the definition of an asset as stipulated in FASB Concepts Statement No. 6. If applicable, we assess the regulatory and approval process including any known constraints and impediments to approval. We also consider the shelf life of the product in relation to the expected timeline for approval. We review our inventory for excess or obsolete inventory and write down obsolete or otherwise unmarketable inventory to its estimated net realizable value.

During the second quarter of 2006, certain manufacturing improvements were made to the equipment in the Company’s single product manufacturing facility that requires regulatory action. The Company plans to file a supplemental biologics license application (“sBLA”) with the FDA in the middle of August 2006, and we expect to be able to distribute ERBITUX produced with the improved equipment approximately thirty days after the submission date. As of June 30, 2006, there was approximately $16.2 million of inventory produced using this equipment.

In June 2006, the Company began producing ERBITUX for commercial use at its multiple product manufacturing facility (“BB50”), located in Branchburg, New Jersey. The Company expects to file a sBLA with the FDA for approval of BB50 in the first quarter of 2007. Until such time as the Company receives approval of BB50 from the FDA, the ERBITUX inventory produced in BB50 cannot be used for commercial distribution. Based on management’s current expectations, the Company expects that the costs of such inventory will be fully realizable once the Company obtains approval of BB50. Therefore, in June 2006, the Company capitalized the costs of producing ERBITUX in BB50, which amounted to approximately $10.5 million. This amount is classified in Other assets in the Company’s Consolidated Balance Sheets as it is not expected to be sold within one year. The Company will continue to capitalize the costs of producing ERBITUX in BB50 as long as management can conclude that the costs of such inventory will be fully realizable in the future.

7

IMCLONE SYSTEMS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(UNAUDITED)

(3)Property, Plant and Equipment

Property, plant and equipment are recorded at cost and consist of the following: (in thousands)

	June 30, 2006			December 31, 2005
Land	$	4,899			$	4,899
Building.	280,205				67,597
Leasehold improvements	13,966				13,969
Machinery and equipment	158,726				62,806
Furniture and fixtures	5,671				4,596
Construction in progress	41,296				318,446
Total Cost	504,763				472,313
Less accumulated depreciation and amortization	(80,230		)		(65,718		)
Property, plant and equipment, net	$	424,533			$	406,595

In June 2006, the Company began to use a portion of BB50 for the commercial production of ERBITUX. BB50 is a 250,000 square foot multiple product manufacturing facility located in Branchburg, New Jersey, with capacity of up to 110,000 liters (production volume). BB50 has the capacity for three distinct suites capable of producing up to three different products concurrently. The Company completed validation and commissioning of Suite 1 during the second quarter of 2006, where it is now producing ERBITUX for commercial distribution. Suite 2 has been fitted with equipment and it is estimated that commissioning and validation of this suite will begin in 2007. We expect that Suite 2 will be used for purposes of producing our pipeline products. At this point, Suite 3 remains vacant until further determination of its ultimate use. In June 2006, the Company transferred, from construction in progress, the cost associated with BB50 into the appropriate categories, with the exception of certain costs, primarily related to the equipment that resides in Suite 2. Such equipment will be put into service once the Company commissions and validates such equipment for the eventual manufacturing of our pipeline products. The total cost of constructing BB50 through June 30, 2006 amounted to approximately $330 million, including approximately $34.8 million of costs related to the commissioning and validation of Suite 1 and $22.7 million of capitalized interest.

The process of preparing consolidated financial statements in accordance with U.S. generally accepted accounting principles requires the Company to evaluate the carrying values of its long-lived assets. The recoverability of the carrying values of long-lived assets depends on the Company’s ability to earn sufficient returns on ERBITUX. Based on management’s current estimates, the Company expects to recover the carrying value of such assets.

(4)Withholding Tax Assets and Liability

On March 13, 2003, the Company initiated discussions with the Internal Revenue Service (the “IRS”) relating to federal income taxes not withheld because one or more of the Company’s employees who exercised certain non-qualified stock options in 1999 and 2000 failed to pay federal income taxes for those years. Subsequently, the Company became aware of another potential income and employment tax withholding liability associated with the exercise of certain warrants granted in the early years of the Company’s existence that were held by certain former officers, directors and employees. After disclosure to

8

IMCLONE SYSTEMS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(UNAUDITED)

the IRS in 2003, the IRS commenced audits of the Company’s income tax and employment tax returns for the years 1999-2001. On February 8, 2006, the Company received a draft of the IRS’s report of its preliminary findings which indicated that the IRS, in addition to imposing liability on the Company for taxes not withheld, intended to assert penalties with respect to both the failure to withhold on non-qualified stock options and the failure to report and withhold on the warrants described above. On March 14, 2006, the Company reached an agreement in principle with the IRS to resolve the employment tax audit, which includes the Company’s agreement to the imposition of an accuracy-related penalty under Section 6662 of the Internal Revenue Code. Under this agreement, the Company’s liability to the IRS was calculated to be approximately $32,000,000. The Company had previously recorded a withholding tax liability of $18,096,000 and a withholding tax asset of $274,000 in its consolidated Balance Sheet as of December 31, 2004. Based on the agreement in principle reached with the IRS, the Company eliminated the withholding tax asset of $274,000 and recorded an additional withholding tax liability of $13,904,000, or a total of $32,000,000, in its consolidated Balance Sheet as of December 31, 2005. As a result, the Company recorded in the fourth quarter of 2005 a net withholding tax expense of $14,178,000. On April 19, 2006, the Company signed an agreement with the IRS to resolve the employment tax audit. Pursuant to such agreement the Company paid $28,655,509 to the IRS on April 21, 2006, and on April 28, 2006, the Company paid the IRS $3,080,789 consisting of interest.

On March 31, 2003, the Company received notification from the SEC that it was conducting an informal inquiry into the matters discussed above and, subsequently, the Company received and responded to a request from the SEC for the voluntary production of related documents and information. There have been no other requests for documents or information or other developments in connection with this SEC informal inquiry since April 2003.

(5)Share-Based Compensation Plans

Effective January 1, 2006, the Company adopted the provisions of FASB No. 123 (revised 2004), Share-Based Payment (“SFAS 123R”) using the modified prospective transition method. Under this method, prior periods are not revised for comparative purposes and the Company recognizes compensation cost using a fair-value based method for all share-based payments granted after December 31, 2005, plus any awards granted to employees prior to December 31, 2005 that remain unvested at that time. Prior to January 1, 2006, the Company accounted for its share-based compensation plans in accordance with the provisions of Accounting Principles Board (“APB”) Opinion No. 25. “Accounting for Stock Issued to Employees”, and related interpretations including Statement of Financial Accounting Standards Board Interpretation No. 44, “Accounting for Certain Transactions Involving Stock Compensation—An Interpretation of APB Opinion No. 25”. On November 10, 2005, the FASB issued FASB Staff Position No. FAS 123(R)-3, “Transition Election Related to Accounting for Tax Effects of Share-Based Payment Awards.” The Company has elected to adopt the alternative transition method provided in this FASB Staff Position for purposes of calculating the pool of excess tax benefits available to absorb tax deficiencies recognized subsequent to the adoption of SFAS 123R.

The Company has three types of share-based compensation plans: stock option plans, an employee stock purchase plan and effective as of January 1, 2006, a retention plan.

9

IMCLONE SYSTEMS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(UNAUDITED)

Stock Option Plans

In February 1996, the Company’s Board of Directors adopted and the shareholders thereafter approved an Incentive Stock Option Plan and Non-Qualified Stock Option Plan (the “96 Plans”). In May 1998, the Company’s Board of Directors adopted an additional Non-Qualified Stock Option Plan (the “98 Plan”), which shareholders were not required to approve. On June 11, 2002, the shareholders approved and the Company adopted the 2002 Stock Option Plan (the “02 Plan”). Effective with the adoption of the 02 Plan, the Company will not award new grants from the 96 Plans or the 98 Plan. The 02 Plan provides for the granting of both incentive stock options and non-qualified stock options to purchase, subject to adjustment under the plan, 3,300,000 shares of the Company’s common stock to employees, directors, consultants and advisors of the Company. Any common stock subject to an option which is cancelled, forfeited or expires prior to exercise, whether such option was granted under this plan or the 96 Plans or the 98 Plan, shall again become available for grant under the 02 Plan. Options granted under the 02 Plan become fully vested and exercisable upon the occurrence of a change in control, as defined. Incentive stock options granted under the 02 Plan may not exceed 825,000 shares of common stock, may not be granted at a price less than the fair market value of the stock at the date of grant and may not be granted to non-employees. In September 2003, the shareholders approved an amendment to the 02 Plan that increased the maximum total number of shares of common stock currently available for grant of options under the plan from 3,300,000 shares to 6,600,000 shares, and increased the number of shares of common stock with respect to which incentive stock options may be granted under the plan from 825,000 shares to 1,650,000 shares.

In November 2001, the Board of Directors approved the amendment of the 96 Plans and the 98 Plan whereby upon the occurrence of a change in control, as defined in the amended plan documents, each outstanding option under the 96 Plans and the 98 Plan shall become fully vested and exercisable.

On October 17, 2005, the Compensation Committee of the Board of Directors approved the adoption of a stock option plan for the sole purpose of making one-time grants of stock options to newly hired key employees who have not previously been employees or directors of the Company as an inducement to such persons entering into employment with the Company (the “Inducement Plan”), in accordance with NASDAQ Marketplace Rule 4350(i)(1)(A)(iv). The Inducement Plan permits the Company to issue up to a total of 600,000 “inducement” options to eligible participants to purchase shares of common stock of the Company on terms and conditions set forth therein and in individual award agreements under the Inducement Plan, in each case on terms commensurate with options granted under the 02 Plan.

Combined, the 96 Plans, as amended, the 98 Plan, as amended, and the 02 Plan, as amended, and the Inducement Plan (the “Stock Options Plans”) provide as of June 30, 2006 for the granting of options to purchase up to 34,500,000 shares of common stock to employees, directors, consultants and advisors of the Company. Incentive stock options may not be granted at a price less than the fair market value of the stock at the date of grant and may not be granted to non-employees. Options under all the plans, unless earlier terminated, expire ten years from the date of grant. Options granted under these plans generally vest over one-to-four-year periods.

On December 16, 2005, the Company’s Board of Directors approved the acceleration of vesting of unvested stock options with exercise prices equal to or greater than $33.44 per share outstanding as of December 16, 2005 that had been previously awarded to Company employees and other eligible participants, including officers and non-employee directors. Options to purchase approximately 2,805,169

10

IMCLONE SYSTEMS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(UNAUDITED)

shares of the Company’s common stock were subject to this acceleration. Of this amount, approximately 163,750 options are held by non-employee directors, with a weighted average exercise price of $45.00 per share, and 628,347 options are held by officers of the Company with a weighted average exercise price of $44.32 per share. The Board required each non-employee director and, as a condition to continued employment, each officer of the Company, to agree to refrain from selling, transferring, pledging or otherwise disposing of shares of Company common stock acquired upon any exercise of subject stock options (other than sales by such persons to fund the exercise price or to satisfy minimum statutory withholding on such exercise, each in accordance with the applicable Plan and the Company’s existing policies and procedures) until the date on which the exercise would have been permitted under the stock option’s pre-acceleration vesting terms or pursuant to the Company’s Change-in-Control Plan or, if earlier, the officer’s last day of employment with, or director’s last day of service as a director of, the Company. The decision to accelerate vesting of these stock options, which were “out-of-the-money”, was made primarily to minimize future compensation expense that the Company would otherwise have been required to recognize in its Consolidated Statements of Income pursuant to SFAS 123R, which the Company adopted on January 1, 2006. The Company estimates that the aggregate future expense that will be eliminated as a result of this acceleration of vesting is approximately $22.5 million in 2006 and $9.5 million in 2007.

Employee Stock Purchase Plan

In April 1998, the Company’s Board of Directors adopted the ImClone Systems Incorporated 1998 Employee Stock Purchase Plan (the “ESPP”), subject to shareholders’ approval, which was received in May 1998. The ESPP, as amended, allows eligible employees to purchase shares of the Company’s common stock through payroll deductions at the end of quarterly purchase periods. To be eligible, an individual must be an employee, work more than 20 hours per week for at least five months per calendar year and not own greater than 5% of the Company’s common stock. Pursuant to the ESPP, the Company has reserved 1,000,000 shares of common stock for issuance. Prior to the first day of each quarterly purchase period, each eligible employee may elect to participate in the ESPP. The participant is granted an option to purchase a number of shares of common stock determined by dividing each participant’s contribution accumulated prior to the last day of the quarterly period by the purchase price. The participant has the ability to withdraw from the ESPP until the second-to-last day of the quarterly purchase period. The purchase price is equal to 85% of the market price per share on the last day of each quarterly purchase period. An employee may purchase stock from the accumulation of payroll deductions up to the lesser of 15% of such employee’s compensation or $25,000 in aggregate purchase price, per year.

Retention Plan

In January 2006, the Compensation Committee of the Board of Directors approved a Retention Plan, effective as of January 1, 2006, for performance periods ending December 31, 2007 and December 31, 2008 (each, a “Performance Period”). The Plan is intended to reward employees for achieving specified performance goals over specified performance periods. Specifically, the Compensation Committee approved the share performance criteria that will be used to determine cash bonus awards under the Retention Plan, and the terms of the individual awards to eligible employees under the Retention Plan for each of the two Performance Periods. Cash awards under the Retention Plan will depend on the performance of the Company’s common stock against specified targets, generally measured by comparing

11

IMCLONE SYSTEMS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(UNAUDITED)

the Company’s share price at the beginning of the Performance Period to the Company’s share price at the conclusion of the Performance Period, in each case based on a 30-day average. In particular, at the end of an applicable Performance Period, the percentage of the cash award earned (if any) and, correspondingly, the amount of the actual award payouts to an employee for such Performance Period will be (i) equal to the employee’s target award opportunity, (ii) greater than the target award opportunity (but in no event more than 150% of the target award opportunity), or (iii) zero, in each case directly corresponding to actual Company common stock performance at the conclusion of the Performance Period compared to the beginning of the Performance Period. No awards will be payable in respect of a Performance Period if the Company’s share price at the conclusion of the Performance Period is less than the share price at the beginning of the Performance Period. The Company’s share price at the beginning of the Performance Periods was calculated to be $32.99. Special measurement dates and payment conditions apply in the event of a change in control of the Company occurring during a Performance Period. The Company has determined that awards granted under this plan should be classified as liability awards.

The following table summarizes the effect of compensation cost arising from share-based payment arrangements on the Company’s statements of income for the Company’s Stock Option Plans, the ESPP and the Retention Plan:

	Three Months Ended					Six Months Ended
	June 30, 2006		June 30, 2005			June 30, 2006		June 30, 2005
	(In Thousands)
Research and development	$	508,000		$	—	$	1,023,000		$	—
Clinical and regulatory	351,000			—		669,000			—
Marketing, general and administrative	1,355,000			—		2,413,000			—
Total	$	2,214,000		$	—	$	4,105,000		$	—

In addition, the Company capitalized, during the three and six months ended June 30, 2006, $355,000 and $524,000, respectively, as part of the cost of inventory and $78,000 and $204,000, respectively, in property, plant and equipment.

As a result of adopting SFAS 123R, the Company’s income before income taxes and net income for the three months ended June 30, 2006 was $2,214,000 and $1,840,000 lower, respectively, than if it had continued to account for share-based compensation in accordance with the provisions of APB Opinion 25. The Company’s income before income taxes and net income for the six months ended June 30, 2006 was $4,105,000 and $3,491,000 lower, respectively, than if it had continued to account for share-based compensation in accordance with the provisions of APB Opinion 25. Basic and diluted income per share for the three months ended June 30, 2006, would have been $0.46 and $0.44, respectively, if the Company had not adopted SFAS 123R, compared to reported basic and diluted income per share of $0.44 and $0.42, respectively. Basic and diluted income per share for the six months ended June 30, 2006, would have been $3.22 and $2.97, respectively, if the Company had not adopted SFAS 123R, compared to reported basic and diluted income per share of $3.18 and $2.93, respectively. In addition, for the six months ended June 30, 2006, the adoption of SFAS 123R resulted in net cash provided by operating activities being lower and net cash provided by financing activities being higher by approximately $48,495,000.

Prior to the adoption of SFAS 123R, all tax benefits for deductions resulting from the exercise of stock options were presented as operating cash flows on the Consolidated Statement of Cash Flows. Upon

12

IMCLONE SYSTEMS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(UNAUDITED)

adoption of SFAS 123R, cash flows resulting from the tax benefits of tax deductions are classified as financing cash flows.

Determining Fair Value

Valuation and Amortization Method:   The fair value of stock options granted under the Company’s Stock Option Plans and the ESPP is estimated using the Black-Scholes option pricing model. The fair value of stock options granted after January 1, 2006 is amortized on a straight-line basis. The fair value of stock options granted before January 1, 2006 is amortized using the graded vesting attribution approach. Compensation expense is amortized over the requisite service periods of the awards, which are generally the vesting periods. The fair value of awards granted under the Retention Plan were calculated using a Monte-Carlo simulation pricing model. The fair value of these awards is being amortized based on the proportionate amount of the requisite service period that has been rendered to date for each respective performance period.

Expected Term:   The expected term of an employee share option is the period of time for which the option is expected to be outstanding. The Company has made a determination of expected term by analyzing employees’ historical exercise experience and post-vesting employment termination behavior from its history of grants and exercises in the Company’s option database. The historical pattern of option exercises has been analyzed in an effort to determine if there were any discernable patterns of activity based on certain demographic characteristics such as employees’ length of service, salary and job level.

Expected Volatility:   Volatility is a measure of the amount by which a financial variable, such as share price, has fluctuated (historical volatility) or is expected to fluctuate (expected volatility). The expected volatility of stock option awards at the date of grant is estimated based on the implied volatility of greater than one-year publicly traded options. The decision to use implied volatility was based upon the availability of actively traded options on the Company’s common stock and the assessment that implied volatility is more representative of future stock price trends than historical volatility. Prior to the adoption of SFAS 123R, the Company calculated expected volatility using only historical stock price volatility.

Risk-Free Interest Rate:   The risk-free interest rate used in the Black-Scholes option pricing model is based on the implied yield available on U.S. Treasury zero-coupon issues with a remaining term equal to the expected term used. The risk free rate used in the Monte-Carlo valuation model is based on the implied yield in effect at the time of grant from the constant maturity treasury yield curve over the contractual terms of the award.

Dividends:   Cash dividends have never been declared on the Company’s common stock and the Company has no present intention to declare cash dividends in the foreseeable future. Consequently, an expected dividend yield of zero was used in both the Black-Scholes and Monte-Carlo valuation models.

Forfeitures:   The Company uses historical data to estimate pre-vesting option forfeitures. Share-based compensation expense is recorded only for those awards that are expected to vest. The Company’s pre-vesting forfeiture rate used was 10.7%.

13

IMCLONE SYSTEMS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(UNAUDITED)

The following assumptions were used to estimate the fair value of options granted under the Company’s Stock Option Plans for the three and six months ended June 30, 2006 and 2005:

	Stock Options
	Three Months Ended					Six Months Ended
	June 30, 2006		June 30, 2005			June 30, 2006		June 30, 2005
Expected term (years)	3.95-4.56			4.97		3.95-5.72			4.31
Expected volatility	27.45	%		82.76	%	27.45%-42.70	%		83.00	%
Risk free interest rate	5.19%-5.21	%		3.67	%	4.31%-5.21	%		3.52	%
Expected dividend rate	0	%		0	%	0	%		0	%

The assumptions used in the Monte-Carlo simulation modeling to estimate the fair value of awards under the Retention Plan for the three and six months ended June 30, 2006 were: expected volatility of 28.25%, risk free interest rate ranging from 5.28% to 5.35% and expected dividend yield of 0%. The fair value of the Company’s ESPP awards was calculated using the intrinsic value of the common stock purchased on June 30, 2006 based on the fact that the Company’s offering period is three months and the ESPP does not contain a look-back provision.

Stock Option Activity and Share-Based Compensation Expense

Stock option activity for the six months ended June 30, 2006 is summarized as follows:

	Number of Shares		Weighted Average Exercise Price Per Share			Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
						(Years)		(in thousands)
Outstanding at December 31, 2005	12,619,193			$	37.38
Granted	1,395,282			35.05
Exercised	(718,470	)		17.53
Forfeitures	(799,626	)		47.26
Expired	(436	)		6.01
Outstanding at June 30, 2006	12,495,943			$	37.63		6.46		$	75,620
Vested and expected to vest	12,262,217			$	37.69		6.34		$	74,575
Exercisable at June 30, 2006	10,939,108			$	38.32		6.06		$	66,282

The weighted average fair value of options granted during the three months ended June 30, 2006 and 2005 was $12.26 and $21.16, respectively. The weighted average fair value of options granted during the six months ended June 30, 2006 and 2005 was $14.82 and $26.34, respectively. The aggregate intrinsic value of options outstanding at June 30, 2006 is calculated as the difference between the exercise price of the underlying options and the market price of the Company’s common stock for the 5,890,011 shares that had exercise prices that were lower than the $38.64 market price of our common stock at June 30, 2006. The total intrinsic value of options exercised during the three months ended June 30, 2006 and 2005 was $3,167,000 and $4,739,000, respectively, determined as of the date of exercise. The total intrinsic value of options exercised during the six months ended June 30, 2006 and 2005 was $13,222,000 and $12,791,000, respectively, determined as of the date of exercise.

14

IMCLONE SYSTEMS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(UNAUDITED)

The Company recognized for the three and six months ended June 30, 2006 approximately $1,728,000 and $3,299,000, respectively in share-based compensation expense, net of amounts capitalized, for stock options granted under the Company’s Stock Option Plans. As of June 30, 2006, there was $15,280,000 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Company’s Stock Option Plans. This amount assumes the Company’s expected forfeiture rate. That cost is expected to be recognized over a weighted average period of 2.3 years. The Company utilizes newly issued shares to satisfy the exercise of stock options.

Upon issuance of the awards, the grant date fair value for the Retention Plan was approximately $3.7 million. The fair value (based on the June 30, 2006 valuation) of the Retention Plan awards outstanding at June 30, 2006 was approximately $5,111,000. The combined fair value of the Retention Plan awards that were cancelled during the six months ended June 30, 2006 was approximately $477,000 (based on the June 30, 2006 valuation). The aggregate intrinsic value of the awards outstanding at June 30, 2006, all of which are not vested, is approximately $7,258,000 which is calculated based on the percentage that the 30 day average closing stock price preceding June 30, 2006 exceeded the trigger price of $32.99. The aggregate intrinsic value of the awards expected to vest at June 30, 2006 is approximately $5,795,000. The weighted average remaining contractual term for both the awards outstanding and the awards that are vested and expected to vest at June 30, 2006 is two years.

The Company recognized for the three and six months ended June 30, 2006 approximately $456,000 and $737,000, respectively in share-based compensation expense, net of amounts capitalized, for the Retention Plan. As of June 30, 2006, there was $3,221,000 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Retention Plan. This amount assumes the Company’s expected forfeiture rate. The costs associated with the awards are expected to be recognized over the Performance Periods.

During the three and six months ended June 30, 2006, the Company granted 6,245 and 15,055 shares, respectively for the ESPP for a total of 198,450 shares that have been issued under the plan and recognized approximately $30,000 and $69,000, respectively, in share-based compensation expense, net of amounts capitalized. The Company utilizes newly issued shares to satisfy the issuance of shares under the ESPP.

15

IMCLONE SYSTEMS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(UNAUDITED)

Comparable Disclosures

The following table illustrates the pro forma effect on the Company’s net income and net income per share as if the Company had adopted the fair value based method of accounting for stock-based compensation under Statement of Financial Accounting Standards No. 123 “Accounting for Stock-Based Compensation” for the three and six months ended June 30, 2005. See the assumptions disclosed previously in this note that were used to estimate the fair value of options granted under the stock option plans for the three and six months ended June 30, 2005.

	Three Months Ended June 30, 2005				Six Months Ended June 30, 2005
	(In thousands, except per share amounts)
Net Income
Net Income, as reported		$	26,031			$	54,851
Add: Stock-based employee compensation expense included in net income, tax effected		—				—
Deduct: Total share-based employee compensation expense determined under fair value method for all awards, net of income taxes		(13,096		)		(29,045		)
Pro forma net income		$	12,935			$	25,806
Net income per share
Basic—as reported		$	0.31			$	0.66
Basic—pro forma		$	0.15			$	0.31
Diluted—as reported		$	0.30			$	0.63
Diluted—pro forma		$	0.15			$	0.31

The calculation of diluted pro forma income per common share for the three and six months ended June 30, 2005 excludes the effect of the 13¤8% convertible notes because their inclusion would have had an anti-dilutive effect.

(6)Income Per Common Share

Basic income per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted income per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the period increased to include all additional common shares that would have been outstanding assuming potentially dilutive common share equivalents had been issued. Dilutive common share equivalents include 1) the dilutive effect of in-the-money shares related to stock options, which is calculated based on the average share price for each period using the treasury stock method. Under the treasury stock method, the exercise price of an option, the average amount of compensation cost, if any, for future service that the Company has not yet recognized, and the amount of benefits that would be recorded in additional paid-in capital, if any, when the option is exercised, are assumed to be used to repurchase shares in the current period and 2) the conversion of convertible debt which is done on an “if-converted” basis. In addition, in computing the dilutive effect of convertible debt, the numerator is adjusted to add back the after-tax amount of interest recognized in the period. For the three months ended June 30, 2006 and 2005, there were an

16

IMCLONE SYSTEMS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(UNAUDITED)

aggregate of 8,080,000 and 8,956,000, respectively, potential common shares, excluded from the diluted income per share computation because their inclusion would have had an anti-dilutive effect. For the six months ended June 30, 2006 and 2005, there were an aggregate of 8,295,000 and 7,742,000, respectively, potential common shares, excluded from the diluted income per share computation because their inclusion would have had an anti-dilutive effect.

Basic and diluted income per common share (EPS) were computed using the following: (in thousands, except per share data)

	Three Months Ended June 30				Six Months Ended June 30
	2006		2005		2006		2005
EPS Numerator—Basic:
Net Income	$	37,209	$	26,031	$	266,800	$	54,851
EPS Denominator—Basic:
Weighted-average number of shares of common stock outstanding	84,072		83,616		83,849		83,448
EPS Numerator—Diluted:
Net Income	$	37,209	$	26,031	$	266,800	$	54,851
Adjustment for interest, net of amounts capitalized and income tax effect	1,597		1,676		2,871		3,461
Net income, adjusted	$	38,806	$	27,707	$	269,671	$	58,312
EPS Denominator—Diluted:
Weighted-average number of shares of common stock outstanding	84,072		83,616		83,849		83,448
Effect of dilutive securities:
Stock options	1,776		2,122		1,816		2,578
Convertible subordinated notes	6,336		6,336		6,336		6,336
Dilutive potential common shares	8,112		8,458		8,152		8,914
Weighted-average common shares and dilutive potential common shares	92,184		92,074		92,001		92,362
Basic income per common share	$	0.44	$	0.31	$	3.18	$	0.66
Diluted income per common share	$	0.42	$	0.30	$	2.93	$	0.63

(7)Taxes

The Company’s estimated annual effective income tax rate for 2006 is approximately 15% which excludes the effect of the partial release of our valuation allowance described below. The estimated effective tax rate used for the first quarter of 2006 was 13%; as a result, our effective tax rate for the second quarter of 2006 is 21%. The estimates for the quarter and full-year rates are higher than the Company’s previous estimate of 13% due to higher projected income for the full-year 2006 than previously estimated with no additional operating tax attributes to utilize.

In the first quarter of 2006, the Company released a portion of its valuation allowance against our total deferred tax assets because we determined, based on revised expectations of our projected future earnings, that it is more likely than not that we will realize the benefit of these deferred tax assets, which

17

IMCLONE SYSTEMS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(UNAUDITED)

amounted to approximately $99.5 million. Our conclusion to release a portion of our valuation allowance against our deferred tax assets is supported by several events that transpired during the first quarter of 2006. In addition to obtaining approval from the FDA for ERBITUX in a second indication in March of 2006, the in-market sales for ERBITUX during this period exceeded our expectations and have continued to show strong growth in the marketplace. Most importantly, a potential competitor released certain clinical data on their competing product, which gave us the ability to further understand the competitive threats posed by this potential product. Therefore, our decision is supported by a combination of better than expected in-market sales that we believe will be sustainable in the future coupled with the ability to further refine our future financial projections and assumptions related to our competition. The financial projections supporting our conclusion to release a portion of our valuation allowance contain significant assumptions based on current facts about our market share and our competitive landscape. If such assumptions were to differ significantly, it may have a material impact on our ability to realize our deferred tax assets. The projected tax rate for 2006 is less than the federal statutory rate of 35%, mainly due to the utilization of fully reserved deferred tax assets.

(8)Collaborative Agreements

(a) Merck KGaA

In April 1990, the Company entered into an agreement with Merck KGaA relating to the development and commercialization of BEC2 and the recombinant gp75 antigen. Under this agreement:

·we granted Merck KGaA a license, with the right to sublicense, to make, have made, use, sell, or have sold BEC2 and gp75 antigen outside North America;

·we granted Merck KGaA a license, without the right to sublicense, to use, sell, or have sold, but not to make, BEC2 within North America in conjunction with ImClone Systems;

·we retained the rights, (1) without the right to sublicense, to make, have made, use, sell, or have sold BEC2 in North America in conjunction with Merck KGaA and (2) with the right to sublicense, to make, have made, use, sell, or have sold gp75 antigen in North America;

·we were required to give Merck KGaA the opportunity to negotiate a license in North America to gp75 antigen before granting such a license to any third party.

In return, Merck KGaA:

·made research support payments to us totaling $4,700,000;

·was required to make milestone payments to us of up to $22,500,000, of which $5,000,000 was received through June 30, 2006 based on milestones achieved in the product development of BEC2;

·was required to make royalty payments to us on all sales of the licensed products outside North America, if any, with a portion of the earlier funding received under the agreement being creditable against the amount of royalties due.

Following an analysis of the results of various clinical studies involving BEC2 and work on the recombinant gp75 antigen, the Company and Merck KGaA determined to discontinue their further development and terminated the related agreement in the fourth quarter of 2005. Approximately $1.6 million of deferred revenue related to this agreement was recorded as revenue upon the cancellation of the

18

IMCLONE SYSTEMS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(UNAUDITED)

contract. The Company incurred expenses of $0 and approximately $7,000 for the three months ended June 30, 2006 and 2005, respectively, and expenses of $0 and approximately $29,000 for the six months ended June 30, 2006 and 2005, respectively related to this contract.

In December 1998, the Company entered into a development and license agreement with Merck KGaA with respect to ERBITUX . In exchange for granting Merck KGaA exclusive rights to market ERBITUX outside of the United States and Canada and co-exclusive development rights in Japan, the Company has received $30,000,000 through June 30, 2006 in up-front cash fees and early cash payments based on the achievement of defined milestones. An additional $30,000,000 has been received through June 30, 2006 based upon the achievement of further milestones for which Merck KGaA received equity in the Company. The equity interests underlying the milestone payments were priced at varying premiums to the then-market price of the common stock depending upon the timing of the achievement of the respective milestones.

Merck KGaA pays the Company a royalty on its sales of ERBITUX outside of the United States and Canada. In August 2001, the Company and Merck KGaA amended this agreement to provide, among other things, that Merck KGaA may manufacture ERBITUX for supply in its territory and may utilize a third party to do so upon the Company’s reasonable acceptance. The amendment further released Merck KGaA from its obligations under the agreement relating to providing a guaranty under a $30,000,000 credit facility relating to the build-out of BB36. In addition, the amendment provides that the companies have co-exclusive rights to ERBITUX in Japan, including the right to sublicense and Merck KGaA waived its right of first offer in the case of a proposed sublicense by the Company of ERBITUX in the Company’s territory. In consideration for the amendment, the Company agreed to a reduction in royalties’ payable by Merck KGaA on sales of ERBITUX in Merck KGaA’s territory.

In September 2002, the Company entered into a binding term sheet, effective as of April 15, 2002, for the supply of ERBITUX to Merck KGaA, which replaced previous supply arrangements. The term sheet provided for Merck KGaA to purchase bulk and finished ERBITUX ordered from the Company during the term of the December 1998 development and license agreement at a price equal to the Company’s fully loaded cost of goods. The term sheet also provided for Merck KGaA to use reasonable efforts to enter into its own contract manufacturing agreements for supply of ERBITUX and obligates Merck KGaA to reimburse the Company for costs associated with transferring technology and any other services requested by Merck KGaA relating to establishing its own manufacturing or contract manufacturing capacity.

In July 2006, the Company and Merck KGaA entered into agreements amending and supplementing the 1998 development and license agreement. As part of the agreements, the Company consented to Merck KGaA’s sublicense of certain intellectual property rights relating to the development and commercialization of an anti-EGFR antibody to Takeda Pharmaceutical Company. Merck KGaA and Takeda signed an alliance in September 2005 for the development and commercialization of matuzumab (EMD72000), a humanized EGFR-targeting monoclonal antibody. In consideration for the Company’s consent, Merck KGaA agreed to pay the Company EUR 2.5 million within 30 days of the execution of the agreements and a further EUR 5 million within 30 days of the Company’s written consent to the sublicense. In addition, Merck KGaA agreed to increase its fixed royalty to 9.5% on net sales of ERBITUX outside the U.S. and Canada, effective July 1, 2006. The agreements also promote freedom to operate in the development and commercialization of matuzumab outside the United States and Canada and of IMC-11F8 (a fully human EGFR-targeted IgG1 monoclonal antibody being developed by ImClone

19

IMCLONE SYSTEMS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(UNAUDITED)

Systems) within the United States and Canada through the granting of certain reciprocal rights, including the sharing of confidential technical information. This is in addition to the exclusive rights held by the Company to develop and commercialize IMC-11F8 outside of the United States and Canada as recently confirmed in arbitration proceedings described in greater detail under “Part II- Item 1. Legal Proceedings”. The agreements do not extend to key intellectual property rights in the U.S. and Canada, where the Company and its partner Bristol-Myers Squibb continue to hold exclusive licenses to key patents covering certain uses of EGFR-targeted monoclonal antibodies.

Amounts due from Merck KGaA related to these arrangements totaled approximately $8,819,000 and $7,768,000 at June 30, 2006 and December 31, 2005, respectively, and are included in amounts due from corporate partners in the Consolidated Balance Sheets. The Company has a liability due Merck KGaA of $0 and approximately $2,532,000 as of June 30, 2006 and December 31, 2005, respectively.

(b) Bristol-Myers Squibb Company

On September 19, 2001, the Company entered into an acquisition agreement (the “Acquisition Agreement”) with BMS and Bristol-Myers Squibb Biologics Company, a Delaware corporation (“BMS Biologics”), which is a wholly-owned subsidiary of BMS, providing for the tender offer by BMS Biologics to purchase up to 14,392,003 shares of the Company’s common stock for $70.00 per share, net to the seller in cash. BMS accepted these shares for payment on October 29, 2001 on a pro rata basis from all tendering shareholders and those conditionally exercising stock options. In connection with the Acquisition Agreement, the Company entered into a stockholder agreement with BMS and BMS Biologics, dated as of September 19, 2001 (the “Stockholder Agreement”), pursuant to which all parties agreed to various arrangements regarding the respective rights and obligations of each party with respect to, among other things, the ownership of shares of the Company’s common stock by BMS and BMS Biologics. Concurrent with the execution of the Acquisition Agreement and the Stockholder Agreement, the Company entered into the Commercial Agreement with BMS and E.R. Squibb, relating to ERBITUX, pursuant to which, among other things, BMS and E.R. Squibb are co-developing and co-promoting ERBITUX in the United States and Canada with the Company, and are co-developing and co-promoting ERBITUX in Japan with the Company and either together or co-exclusively with Merck KGaA.

On March 5, 2002, the Company amended the Commercial Agreement with E.R. Squibb and BMS. The amendment changed certain economics of the Commercial Agreement and expanded the clinical and strategic roles of BMS in the ERBITUX development program. One of the principal economic changes to the Commercial Agreement is that the Company received payments of $140,000,000 on March 7, 2002 and $60,000,000 on March 5, 2003. Such payments are in lieu of the $300,000,000 milestone payment the Company would have received upon acceptance by the FDA of the ERBITUX BLA under the original terms of the Commercial Agreement. The terms of the Commercial Agreement, as amended on March 5, 2002, are set forth in more detail below.

20

IMCLONE SYSTEMS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(UNAUDITED)

Commercial Agreement

Rights Granted to E.R. Squibb—Pursuant to the Commercial Agreement, as amended on March 5, 2002, the Company granted to E.R. Squibb (1) the exclusive right to distribute, and the co-exclusive right to develop and promote (together with the Company) any prescription pharmaceutical product using the compound ERBITUX (the “product”) in the United States and Canada, (2) the co-exclusive right to develop, distribute and promote (together with the Company and together or co-exclusively with Merck KGaA and its affiliates) the product in Japan, and (3) the non-exclusive right to use the Company’s registered trademarks for the product in the United States, Canada and Japan (collectively, the “territory”) in connection with the foregoing. In addition, the Company agreed not to grant any right or license to any third party, or otherwise permit any third party, to develop ERBITUX for animal health or any other application outside the human health field without the prior consent of E.R. Squibb (which consent may not be unreasonably withheld).

Rights Granted to the Company—Pursuant to the Commercial Agreement, E.R. Squibb has granted to the Company and the Company’s affiliates a license, without the right to grant sublicenses (other than to Merck KGaA and its affiliates for use in Japan and to any third party for use outside the territory), to use solely for the purpose of developing, using, manufacturing, promoting, distributing and selling ERBITUX or the product, any process, know-how or other invention developed solely by E.R. Squibb or BMS that has general utility in connection with other products or compounds in addition to ERBITUX or the product (“E.R. Squibb Inventions”).

Up-Front and Milestone Payments—The Commercial Agreement provides for up-front and milestone payments by E.R. Squibb to the Company of $900,000,000 in the aggregate, of which $200,000,000 was paid on September 19, 2001, $140,000,000 was paid on March 7, 2002, $60,000,000 was paid on March 5, 2003, $250,000,000 was paid on March 12, 2004, and $250,000,000 was paid on March 31, 2006. All such payments are non-refundable and non-creditable.

Distribution Fees—The Commercial Agreement provides that E.R. Squibb shall pay the Company distribution fees based on a percentage of “annual net sales” of the product (as defined in the Commercial Agreement) by E.R. Squibb in the United States and Canada. The distribution fee is 39% of net sales in the United States and Canada. The Commercial Agreement also provides that the distribution fees for the sale of the product in Japan by E.R. Squibb or ImClone Systems shall be equal to 50% of operating profit or loss with respect to such sales for any calendar month. In the event of an operating profit, E.R. Squibb shall pay the Company the amount of such distribution fee, and in the event of an operating loss, the Company shall credit E.R. Squibb the amount of such distribution fee.

Development of the Product—Responsibilities associated with clinical and other ongoing studies is apportioned between the parties as determined by the product development committee described below. The Commercial Agreement provides for the establishment of clinical development plans setting forth the activities to be undertaken by the parties for the purpose of obtaining marketing approvals, providing market support and developing new indications and formulations of the product. After transition of responsibilities for certain clinical and other studies, each party is primarily responsible for performing the studies designated to it in the clinical development plans. In the United States and Canada, the Commercial Agreement provides that E.R. Squibb is responsible for 100% of the cost of all clinical studies other than those studies undertaken post-launch which are not pursuant to an IND (e.g. Phase IV studies), the cost of which is shared equally between E.R. Squibb and ImClone Systems. As between E.R. Squibb and ImClone Systems, each is responsible for 50% of the costs of all studies in Japan. The Company has

21

IMCLONE SYSTEMS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(UNAUDITED)

also agreed, and may agree in the future, to share with E.R. Squibb, on terms other than the foregoing, costs of clinical trials that the Company believes are not potentially registrational but should be undertaken prior to launch in the United States, Canada or Japan. In addition, to the extent that in 2005 and 2006 the Company and BMS exceed the contractual maximum registrational costs for clinical development, the Company has agreed to share such cost with BMS. The Company has recorded expenses of $6,718,000 and $2,459,000 pursuant to such cost sharing agreements for the three months ended June 30, 2006 and 2005, respectively and $13,639,000 and $5,289,000 for the six months ended June 30, 2006 and 2005, respectively. The Company has also incurred $662,000 and $347,000 for the three months ended June 30, 2006 and 2005, respectively, and $1,193,000 and $666,000 for the six months ended June 30, 2006 and 2005, respectively, related to the agreement with respect to Japan. Except as otherwise agreed upon by the parties, the Company will own all registrations for the product and is primarily responsible for the regulatory activities leading to registration in each country. E.R. Squibb will be primarily responsible for the regulatory activities in each country after the product has been registered in that country. Pursuant to the terms of the Commercial Agreement, as amended, Andrew G. Bodnar, M.D., J.D., Senior Vice President, Strategy and Medical & External Affairs of BMS, and a member of the Company’s Board of Directors, is entitled to oversee the implementation of the clinical and regulatory plan for ERBITUX.

Distribution and Promotion of the Product—Pursuant to the Commercial Agreement, E.R. Squibb has agreed to use all commercially reasonable efforts to launch, promote and sell the product in the territory with the objective of maximizing the sales potential of the product and promoting the therapeutic profile and benefits of the product in the most commercially beneficial manner. In connection with its responsibilities for distribution, marketing and sales of the product in the territory, E.R. Squibb is performing all relevant functions, including but not limited to the provision of sales force personnel, marketing, warehousing and physical distribution of the product.

However, the Company has the right, at its election and sole expense, to co-promote with E.R. Squibb the product in the territory. Pursuant to this co-promotion option, which the Company has exercised, the Company is entitled on and after April 11, 2002 (at the Company’s sole expense) to have the Company’s field organization participate in the promotion of the product consistent with the marketing plan agreed upon by the parties, provided that E.R. Squibb retains the exclusive rights to sell and distribute the product. Except for the Company’s expenses incurred pursuant to the co-promotion option, E.R. Squibb is responsible for 100% of the distribution, sales and marketing costs in the United States and Canada, and as between E.R. Squibb and ImClone Systems, each is responsible for 50% of the distribution, sales, marketing costs and other related costs and expenses in Japan. The Company has an established sales force to maximize the potential commercial opportunities for ERBITUX and to serve as a foundation for the marketing of future products derived either from within the Company’s pipeline or through business development opportunities.

Manufacture and Supply—The Commercial Agreement provides that the Company is responsible for the manufacture and supply of all requirements of ERBITUX in bulk form (“API”) for clinical and commercial use in the territory, and that E.R. Squibb will purchase all of its requirements of API for commercial use from the Company. The Company supplies API for clinical use at the Company’s fully burdened manufacturing cost, and supplies API for commercial use at the Company’s fully burdened manufacturing cost plus a mark-up of 10%. Upon the expiration, termination or assignment of any existing agreements between ImClone Systems and third party manufacturers, E.R. Squibb will be responsible for

22

IMCLONE SYSTEMS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(UNAUDITED)

processing API into the finished form of the product. Sales of ERBITUX to BMS for commercial use are reflected in the Company’s Consolidated Statements of Operations as Manufacturing revenue.

Management—The parties have formed the following committees for purposes of managing their relationship and their respective rights and obligations under the Commercial Agreement:

•a Joint Executive Committee (the “JEC”), which consists of certain senior officers of each party. The JEC is co-chaired by a representative of each of BMS and the Company. The JEC is responsible for, among other things, managing and overseeing the development and commercialization of ERBITUX pursuant to the terms of the Commercial Agreement, approving the annual budgets and multi-year expense forecasts, and resolving disputes, disagreements and deadlocks arising in the other committees;

•a Product Development Committee (the “PDC”), which consists of members of senior management of each party with expertise in pharmaceutical drug development and/or marketing. The PDC is chaired by the Company’s representative. The PDC is responsible for, among other things, managing and overseeing the development and implementation of the clinical development plans, comparing actual versus budgeted clinical development and regulatory expenses, and reviewing the progress of the registrational studies;

•a Joint Commercialization Committee (the “JCC”), which consists of members of senior management of each party with clinical experience and expertise in marketing and sales. The JCC is chaired by a representative of BMS. The JCC is responsible for, among other things, overseeing the preparation and implementation of the marketing plans, coordinating the sales efforts of E.R. Squibb and the Company, and reviewing and approving the marketing and promotional plans for the product in the territory; and

•a Joint Manufacturing Committee (the “JMC”), which consists of members of senior management of each party with expertise in manufacturing. The JMC is chaired by the Company’s representative (unless a determination is made that a long-term inability to supply API exists, in which case the JMC will be co-chaired by representatives of E.R. Squibb and the Company). The JMC is responsible for, among other things, overseeing and coordinating the manufacturing and supply of API and the product, and formulating and directing the manufacturing strategy for the product.

Any matter that is the subject of a deadlock (i.e., no consensus decision) in the PDC, the JCC or the JMC will be referred to the JEC for resolution. Subject to certain exceptions, deadlocks in the JEC will be resolved as follows: (1) if the matter was also the subject of a deadlock in the PDC, by the co-chairperson of the JEC designated by the Company, (2) if the matter was also the subject of a deadlock in the JCC, by the co-chairperson of the JEC designated by BMS, or (3) if the matter was also the subject of a deadlock in the JMC, by the co-chairperson of the JEC designated by the Company. All other deadlocks in the JEC will be resolved by arbitration.

Right of First Offer—E.R. Squibb has a right of first offer with respect to the Company’s investigational KDR monoclonal antibodies (such as IMC-1121B) should the Company decide to enter into a partnering arrangement with a third party with respect to IMC-KDR antibodies at any time prior to the earlier to occur of September 19, 2006 and the first anniversary of the date which is 45 days after any date on which BMS’s ownership interest in ImClone Systems is less than 5%. If the Company decides to enter into a partnering arrangement during such period, the Company must notify E.R. Squibb. If E.R. Squibb notifies the Company that it is interested in such an arrangement, the Company will provide its proposed terms to E.R. Squibb and the parties will negotiate in good faith for 90 days to attempt to agree on the terms and

23

IMCLONE SYSTEMS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(UNAUDITED)

conditions of such an arrangement. If the parties do not reach agreement during this period, E.R. Squibb must propose the terms of an arrangement which it is willing to enter into, and if the Company rejects such terms the Company may enter into an agreement with a third party with respect to such a partnering arrangement (provided that the terms of any such agreement may not be more favorable to the third party than the terms proposed by E.R. Squibb).

Right of First Negotiation—If at any time during the restricted period (as defined below), the Company is interested in establishing a partnering relationship with a third party involving certain compounds or products not related to IMC-KDR antibodies, the Company must notify E.R. Squibb and E.R. Squibb will have 90 days to enter into a non-binding agreement with the Company with respect to such a partnering relationship. In the event that E.R. Squibb and ImClone Systems do not enter into a non-binding agreement, the Company is free to negotiate with third parties without further obligation to E.R. Squibb. The “restricted period” means the period from September 19, 2001 until the earliest to occur of (1) September 19, 2006, (2) a reduction in BMS’s ownership interest in ImClone Systems to below 5% for 45 consecutive days, (3) a transfer or other disposition of shares of the Company’s common stock by BMS or any of its affiliates such that BMS and its affiliates own or have control over less than 75% of the maximum number of shares of the Company’s common stock owned by BMS and its affiliates at any time after September 19, 2001, (4) an acquisition by a third party of more than 35% of the outstanding shares, (5) a termination of the Commercial Agreement by BMS due to significant regulatory or safety concerns regarding ERBITUX, or (6) the Company’s termination of the Commercial Agreement due to a material breach by BMS.

Restriction on Competing Products—During the period from the date of the Commercial Agreement until September 19, 2008, the parties have agreed not to, directly or indirectly, develop or commercialize a competing product (defined as a product that has as its only mechanism of action an antagonism of the EGFR) in any country in the territory. In the event that any party proposes to commercialize a competing product or purchases or otherwise takes control of a third party which has developed or commercialized a competing product, then such party must either divest the competing product within 12 months or offer the other party the right to participate in the commercialization and development of the competing product on a 50/50 basis (provided that if the parties cannot reach agreement with respect to such an agreement, the competing product must be divested within 12 months).

Ownership—The Commercial Agreement provides that the Company owns all data and information concerning ERBITUX and the product and (except for the E.R. Squibb Inventions) all processes, know-how and other inventions relating to the product and developed by either party or jointly by the parties. E.R. Squibb, however, has the right to use all such data and information, and all such processes, know-how or other inventions, in order to fulfill its obligations under the Commercial Agreement.

Product Recalls—If E.R. Squibb is required by any regulatory authority to recall the product in any country in the territory (or if the JCC determines such a recall to be appropriate), then E.R. Squibb and ImClone Systems shall bear the costs and expenses associated with such a recall (1) in the United States and Canada, in the proportion of 39% for ImClone Systems and 61% for E.R. Squibb and (2) in Japan, in the proportion for which each party is entitled to receive operating profit or loss (unless, in the territory, the predominant cause for such a recall is the fault of either party, in which case all such costs and expenses shall be borne by such party).

Mandatory Transfer—Each of BMS and E.R. Squibb has agreed under the Commercial Agreement that in the event it sells or otherwise transfers all or substantially all of its pharmaceutical business or

24

IMCLONE SYSTEMS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(UNAUDITED)

pharmaceutical oncology business, it must also transfer to the transferee its rights and obligations under the Commercial Agreement.

Indemnification—Pursuant to the Commercial Agreement, each party has agreed to indemnify the other for (1) its negligence, recklessness or wrongful intentional acts or omissions, (2) its failure to perform certain of its obligations under the agreement, and (3) any breach of its representations and warranties under the agreement.

Termination—Unless earlier terminated pursuant to the termination rights discussed below, the Commercial Agreement expires with regard to the product in each country in the territory on the later of September 19, 2018 and the date on which the sale of the product ceases to be covered by a validly issued or pending patent in such country. The Commercial Agreement may also be terminated prior to such expiration as follows:

•by either party, in the event that the other party materially breaches any of its material obligations under the Commercial Agreement and has not cured such breach within 60 days after notice;

•by E.R. Squibb, if the JEC determines that there exists a significant concern regarding a regulatory or patient safety issue that would seriously impact the long-term viability of all products.

Stockholder Agreement

Pursuant to the Stockholder Agreement, the Company’s Board was increased from ten to twelve members in October 2001. BMS received the right to nominate two directors to the Company’s Board (each a “BMS director”) so long as its ownership interest in ImClone Systems is 12.5% or greater. If BMS’ ownership interest is 5% or greater but less than 12.5%, BMS will have the right to nominate one BMS director, and if BMS’ ownership interest is less than 5%, BMS will have no right to nominate a BMS director. If the size of the Board is increased to a number greater than twelve, the number of BMS directors would be increased, subject to rounding, such that the number of BMS directors is proportionate to the lesser of BMS’ then-current ownership interest and 19.9%. Notwithstanding the foregoing, BMS will have no right to nominate any BMS directors if (1) the Company has terminated the Commercial Agreement due to a material breach by BMS or (2) BMS’ ownership interest were to remain below 5% for 45 consecutive days.

Based on the number of shares of common stock acquired pursuant to the tender offer, BMS has the right to nominate two directors. BMS designated Andrew G. Bodnar, M.D., J.D., BMS’ Senior Vice President, Strategy and Medical & External Affairs, as one of the initial BMS directors. The nomination of Dr. Bodnar was approved by the Board on November 15, 2001. The other BMS director position was initially filled by Peter S. Ringrose, M.A, and Ph.D. Dr. Ringrose retired in 2002 from his position of Chief Scientific Officer and President, Pharmaceutical Research Institute at BMS, and also resigned from his director position with the Company. BMS has not yet designated a replacement to fill Dr. Ringrose’s vacated Board seat.

Voting of Shares—During the period in which BMS has the right to nominate up to two BMS directors, BMS and its affiliates are required to vote all of their shares in the same proportion as the votes cast by all of the Company’s other stockholders with respect to the election or removal of non-BMS directors.

Committees of the Board of Directors—During the period in which BMS has the right to nominate up to two BMS directors, BMS also has the right, subject to certain exceptions and limitations, to have one member of each committee of the Board be a BMS director.

25

IMCLONE SYSTEMS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(UNAUDITED)

Approval Required for Certain Actions—The Company may not take any action that constitutes a prohibited action under the Stockholder Agreement without the consent of the BMS directors, until September 19, 2006 or earlier, if any of the following occurs: (1) a reduction in BMS’s ownership interest to below 5% for 45 consecutive days, (2) a transfer or other disposition of shares of the Company’s common stock by BMS or any of its affiliates such that BMS and its affiliates own or have control over less than 75% of the maximum number of shares of the Company’s common stock owned by BMS and its affiliates at any time after September 19, 2001, (3) an acquisition by a third party of more than 35% of the outstanding shares of the Company’s common stock, (4) a termination of the Commercial Agreement by BMS due to significant regulatory or safety concerns regarding ERBITUX, or (5) a termination of the Commercial Agreement due to a material breach by BMS. Such prohibited actions include (1) issuing additional shares or securities convertible into shares in excess of 21,473,002 shares of the Company’s common stock in the aggregate, subject to certain exceptions; (2) incurring additional indebtedness if the total of (A) the principal amount of indebtedness incurred since September 19, 2001 and then-outstanding, and (B) the net proceeds from the issuance of any redeemable preferred stock then-outstanding, would exceed the Company’s amount of indebtedness for borrowed money outstanding as of September 19, 2001 by more than $500 million; (3) acquiring any business if the aggregate consideration for such acquisition, when taken together with the aggregate consideration for all other acquisitions consummated during the previous twelve months, is in excess of 25% of the Company’s aggregate value at the time the binding agreement relating to such acquisition was entered into; (4) disposing of all or any substantial portion of the Company’s non-cash assets; (5) entering into non-competition agreements that would be binding on BMS, its affiliates or any BMS director; (6) taking certain actions that would have a discriminatory effect on BMS or any of its affiliates as a stockholder; and (7) issuing capital stock with more than one vote per share.

Limitation on Additional Purchases of Shares and Other Actions—Subject to the exceptions set forth below, until September 19, 2006 or, if earlier, the occurrence of any of (1) an acquisition by a third party of more than 35% of the Company’s outstanding shares, (2) the first anniversary of a reduction in BMS’s ownership interest in the Company to below 5% for 45 consecutive days, or (3) the Company’s taking a prohibited action under the Stockholder Agreement without the consent of the BMS directors, neither BMS nor any of its affiliates will acquire beneficial ownership of any shares of the Company’s common stock or take any of the following actions: (1) encourage any proposal for a business combination with the Company’s or an acquisition of our shares; (2) participate in the solicitation of proxies from holders of shares of the Company’s common stock; (3) form or participate in any “group” (within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934) with respect to shares of the Company’s common stock; (4) enter into any voting arrangement with respect to shares of the Company’s common stock; or (5) seek any amendment to or waiver of these restrictions.

The following are exceptions to the standstill restrictions described above: (1) BMS Biologics may acquire beneficial ownership of shares of the Company’s common stock either in the open market or from the Company pursuant to the option described below, so long as, after giving effect to any such acquisition of shares, BMS’ ownership interest would not exceed 19.9%; (2) BMS may make, subject to certain conditions, a proposal to the Board to acquire shares of the Company’s common stock if the Company provides material non-public information to a third party in connection with, or begins active negotiation of, an acquisition by a third party of more than 35% of the outstanding shares; (3) BMS may acquire shares of the Company’s common stock if such acquisition has been approved by a majority of the non-BMS directors; and (4) BMS may make, subject to certain conditions, including that an acquisition

26

IMCLONE SYSTEMS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(UNAUDITED)

of shares be at a premium of at least 25% to the prevailing market price, non-public requests to the Board to amend or waive any of the standstill restrictions described above. Certain of the exceptions to the standstill provisions described above will terminate upon the occurrence of: (1) a reduction in BMS’s ownership interest in the Company to below 5% for 45 consecutive days, (2) a transfer or other disposition of shares of the Company’s common stock by BMS or any of its affiliates such that BMS and its affiliates own or have control over less than 75% of the maximum number of shares owned by BMS and its affiliates at any time after September 19, 2001, (3) a termination of the Commercial Agreement by BMS due to significant regulatory or safety concerns regarding ERBITUX, or (4) a termination of the Commercial Agreement by the Company due to a material breach by BMS.

Option to Purchase Shares in the Event of Dilution—BMS Biologics has the right under certain circumstances to purchase additional shares of common stock from the Company at market prices, pursuant to an option granted to BMS by the Company, in the event that BMS’s ownership interest is diluted (other than by any transfer or other disposition by BMS or any of its affiliates). BMS can exercise this right (1) once per year, (2) if the Company issues shares of common stock in excess of 10% of the then-outstanding shares in one day, and (3) if BMS’s ownership interest is reduced to below 5% or 12.5%. BMS Biologics’ right to purchase additional shares of common stock from the Company pursuant to this option will terminate on September 19, 2006 or, if earlier, upon the occurrence of (1) an acquisition by a third party of more than 35% of the outstanding shares, or (2) the first anniversary of a reduction in BMS’s ownership interest in the Company to below 5% for 45 consecutive days.

Transfers of Shares—Until March 19, 2005, neither BMS nor any of its affiliates were permitted to transfer any shares of the Company’s common stock or enter into any arrangement that transfers any of the economic consequences associated with the ownership of shares. After March 19, 2005, neither BMS nor any of its affiliates may transfer any shares or enter into any arrangement that transfers any of the economic consequences associated with the ownership of shares, except (1) pursuant to registration rights granted to BMS with respect to the shares, (2) pursuant to Rule 144 under the Securities Act of 1933, as amended or (3) for certain hedging transactions. Any such transfer is subject to the following limitations: (1) the transferee may not acquire beneficial ownership of more than 5% of the then-outstanding shares of common stock; (2) no more than 10% of the total outstanding shares of common stock may be sold in any one registered underwritten public offering; and (3) neither BMS nor any of its affiliates may transfer shares of common stock (except for registered firm commitment underwritten public offerings pursuant to the registration rights described below) or enter into hedging transactions in any twelve-month period that would, individually or in the aggregate, have the effect of reducing the economic exposure of BMS and its affiliates by the equivalent of more than 10% of the maximum number of shares of common stock owned by BMS and its affiliates at any time after September 19, 2001. Notwithstanding the foregoing, BMS Biologics may transfer all, but not less than all, of the shares of common stock owned by it to BMS or to E.R. Squibb or another wholly-owned subsidiary of BMS.

Registration Rights—The Company granted BMS customary registration rights with respect to shares of common stock owned by BMS or any of its affiliates. Amounts due from BMS related to this agreement totaled approximately $81,182,000 and $51,503,000 at June 30, 2006 and December 31, 2005, respectively, and are included in amounts due from corporate partners in the Consolidated Balance Sheets.

27

IMCLONE SYSTEMS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(UNAUDITED)

(c)UCB S.A.

In August 2005, the Company entered into a Collaboration and License Agreement with UCB S.A., a company registered in Belgium, for the development and commercialization of CDP-791, UCB’s novel, investigational PEGylated di-Fab antibody targeting the vascular endothelial growth factor receptor-2 (“VEGFR-2”). No upfront or milestone payments are payable under the Agreement. The Agreement provides that the Company and UCB S.A. will share equally all agreed upon development costs for CDP-791 as well as worldwide profits derived from the commercialization of CDP-791 in indications jointly pursued by the parties. The Company will also receive an incremental single-digit royalty on net sales worldwide for such indications. Under certain circumstances, one party may be entitled to pursue (in its territory) an indication independently of the other party, which retains the option to join in the development or commercialization at a later stage. The Company has exclusive commercialization rights to CDP-791 in North America, with UCB receiving such rights in Europe, Japan, and the rest of the world. The Company did not incur any expenses related to this agreement in the three and six months ended June 30, 2006. The Company has a liability of $2,493,000 in accrued expenses as of June 30, 2006 and December 31, 2005 related to this agreement.

Royalty revenue consists of the following: (in thousands)

	Three Months Ended June 30				Six Months Ended June 30
	2006		2005		2006		2005
BMS	$	67,226	$	38,132	$	121,058	$	72,113
Merck KGaA	7,337		3,615		13,613		6,006
Other	51		44		213		44
Total royalty revenue	$	74,614	$	41,791	$	134,884	$	78,163

License fees and milestone revenue consists of the following: (in thousands)

	Three Months Ended June 30				Six Months Ended June 30
	2006		2005		2006		2005
BMS:
ERBITUX license fee revenue	$	33,401	$	24,395	$	177,748	$	47,833
Merck KGaA:
ERBITUX and BEC2 license fee revenue	55		96		111		1,192
Total license fees and milestone revenue	$	33,456	$	24,491	$	177,859	$	49,025

28

IMCLONE SYSTEMS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(UNAUDITED)

Collaborative agreement revenue from partners consists of the following: (in thousands)

	Three Months Ended June 30				Six Months Ended June 30
	2006		2005		2006		2005
BMS:
Drug	$	1,011	$	3,385	$	4,393	$	5,018
ERBITUX clinical and regulatory expenses	2,773		3,383		6,142		6,871
ERBITUX marketing, general and administrative expenses	300		380		551		894
ERBITUX royalty expenses	7,757		4,400		13,968		8,321
Total BMS	11,841		11,548		25,054		21,104
Merck KGaA:
Drug	127		5,490		5,564		8,497
ERBITUX clinical and regulatory expenses	—		386		—		1,058
ERBITUX marketing, general and administrative expenses	36		164		99		220
ERBITUX royalty expenses	1,419		620		3,806		1,167
Total Merck KGaA	1,582		6,660		9,469		10,942
Other	7		1		16		9
Total collaborative agreement revenue	$	13,430	$	18,209	$	34,539	$	32,055

Manufacturing revenue from corporate partners consists of the following: (in thousands)

	Three Months Ended June 30				Six Months Ended June 30
	2006		2005		2006		2005
BMS	$	27,605	$	7,894	$	44,236	$	18,913
Merck KGaA	751		—		3,469		—
Total Manufacturing revenue	$	28,356	$	7,894	$	47,705	$	18,913

Amounts due from corporate partners consists of the following: (in thousands)

	June 30, 2006		December 31, 2005
BMS:
ERBITUX	$	81,182		$	51,503
Merck KGaA
ERBITUX and BEC2	8,819			7,768
Total amounts due from corporate partners	$	90,001		$	59,271

29

IMCLONE SYSTEMS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(UNAUDITED)

Deferred revenue consists of the following: (in thousands)

	June 30, 2006			December 31, 2005
BMS:
ERBITUX commercial agreement	$	428,388			$	356,136
Merck KGaA
ERBITUX development and license agreement	2,778				2,889
Total deferred revenue	431,166				359,025
Less current portion	(145,881		)		(112,624		)
Total long term deferred revenue	$	285,285			$	246,401

(9)Commitments and Contingencies

On October 28, 2003, a complaint was filed by Yeda Research and Development Company Ltd. (“Yeda”) against ImClone Systems and Aventis Pharmaceuticals, Inc. in the U.S. District Court for the Southern District of New York (03 CV 8484). This action does not seek damages, but rather alleges and seeks that three individuals associated with Yeda should also be named as co-inventors on U.S. Patent No. 6,217,866. On June 7, 2005, Yeda amended its U.S. complaint to seek sole inventorship of the subject patent. On November 4, 2005, the Court denied the Company’s motion for summary judgment with respect to this matter, as filed with the Court on June 24, 2005. Hearings on this matter concluded in July 2006; a determination is forthcoming. The Company is vigorously defending against claims asserted in this action. The Company is unable to predict the outcome of this action at the present time.

As previously reported, on March 25, 2004, an action was filed in the United Kingdom Patent Office entitled Referrer’s Statement requesting transfer of co-ownership and amendment of patent EP (UK) 0 667 165 to add three Yeda employees as inventors. Also on March 25, 2004, a German action entitled Legal Action was filed in the Munich District Court I, Patent Litigation Division, seeking to add three Yeda employees as inventors on patent EP (DE) 0 667 165. The Company was not named as a party in these actions that relate to the European equivalent of U.S. Patent No. 6,217,866 discussed above; accordingly, the Company intervened in the U.K. and German actions. Yeda sought to amend its pleadings in the United Kingdom and Germany to seek sole inventorship. Following hearings, both the U.K. and German courts held that Yeda was not entitled to amend its pleadings. Additionally, on or about March 25, 2005 and March 29, 2005, respectively, Yeda filed legal actions in Austria and France against both Aventis and ImClone Systems seeking full inventorship of EP (AU) 0 667 165 and EP (FR) 0 667 165, as well as payment of legal costs and fees. The Company is vigorously defending against claims asserted in these actions. The Company is unable to predict the outcome of these actions at the present time.

As previously reported, on May 4, 2004, a complaint was filed against the Company by Massachusetts Institute of Technology (“MIT”) and Repligen Corporation (“Repligen”) in the U.S. District Court for the District of Massachusetts (04-10884 RGS). This action alleges that ERBITUX infringes U.S. Patent No. 4,663,281, which is owned by MIT and exclusively licensed to Repligen and that the Company should therefore pay damages. On July 28, 2006, the Court denied the Company’s motion for summary judgment seeking to dismiss all claims on the basis that the patent rights at issue were exhausted as a matter of law and granted MIT and Repligen’s cross motion that their patent rights were not exhausted. The case will now proceed to trial on the merits of the Company’s other defenses. The Company is vigorously defending

30

IMCLONE SYSTEMS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(UNAUDITED)

against claims asserted in this action. The Company is unable to predict the outcome of this action at the present time.

No reserve has been established in the financial statements for any of the Yeda or MIT and Repligen actions because the Company does not believe that such a reserve is required to be established at this time under Statement of Financial Accounting Standards No. 5.

The Company is developing a fully human monoclonal antibody, referred to as IMC-11F8, which it intends to commercialize outside the United States and Canada. The Company believes it has the right to do so under its existing development and license agreement with Merck KGaA. However, Merck KGaA had advised the Company that it believed that IMC-11F8 was covered under the development and license agreement with Merck KGaA and that it could therefore have the exclusive rights to market IMC-11F8 outside the United States and Canada and co-exclusive development rights in Japan, for which it would pay the same royalty as it pays for ERBITUX. See “Corporate Collaborations—Collaborations with Merck KGaA”. In agreement with Merck KGaA, the Company submitted this dispute to binding arbitration through an expedited process outside of the provisions of the development and license agreement. Merck KGaA subsequently took the position that the expedited arbitration provision was no longer valid and the Company sued Merck KGaA in federal court in the Southern District of New York to either enforce the arbitration provision previously agreed to or to have the court decide the question of whether IMC-11F8 is or is not covered under the development and license agreement with Merck KGaA. On November 29, 2005, the Court granted the Company’s motion to enforce the expedited arbitration provision previously agreed to, and subsequently appointed a new arbitrator to hear and decide this dispute. On March 31, 2006, the arbitrator decided the matter in favor of the Company, finding that Merck KGaA had no rights to IMC-11F8. That decision is binding and unappealable pursuant to the parties’ arbitration agreement and the parties have subsequently confirmed the arbitration award.

In October 2001, the Company entered into a sublease (the “Sublease”) for a four-story building at 325 Spring Street, New York, New York, which includes approximately 100,000 square feet of usable space. The Sublease has a term of 22 years, followed by two five-year renewal option periods. In order to induce the sublandlord to enter into the Sublease, the Company made a loan to the sublandlord in the principal amount of a $10,000,000 note receivable, of which $8,538,000 is outstanding as of June 30, 2006. The loan is secured by a leasehold mortgage on the prime lease as well as a collateral assignment of rents by the sublandlord. The loan is payable by the sublandlord over 20 years and bears interest at 51¤2% in years one through five, 61¤2% in years six through ten, 71¤2% in years eleven through fifteen and 81¤2% in years sixteen through twenty. In addition, the Company paid the owner a consent fee in the amount of $500,000. Effective March 1, 2005, the Company amended the Sublease to add an additional 6,500 square feet of space upon all the same terms and conditions set forth in the Sublease. In connection with this amendment, the Company paid an up-front fee of $1,690,000 which is being amortized, as a reduction in lease expense, over the respective term of the Sublease. The future minimum lease payments remaining at June 30, 2006, are approximately $47,545,000. The Company is in the process of developing the property for occupancy by its research department.

31

IMCLONE SYSTEMS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(UNAUDITED)

(10)Employee Benefit Plans

Defined Contribution Plan

All employees of the Company who meet certain minimum age and period of service requirements are eligible to participate in a 401(k) defined contribution plan. The 401(k) plan allows eligible employees to defer up to 25 percent of their annual compensation, subject to certain limitations imposed by federal law. The amounts contributed by employees are immediately vested and non-forfeitable. Under the 401(k) plan, the Company, at management’s discretion, may match employee contributions and/or make discretionary contributions. Neither the employee contributions nor voluntary matching contributions are invested in the Company’s securities. Total expense incurred by the Company was $484,000 and $499,000 for the three months ended June 30, 2006 and 2005, respectively, and $1,166,000 and $1,011,000 for the six months ended June 30, 2006 and 2005, respectively.

32

Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis is provided to further the reader’s understanding of the consolidated financial statements, financial condition and results of operations of ImClone Systems in this Quarterly Report on Form 10-Q. This discussion should be read in conjunction with the consolidated financial statements and the accompanying notes included in our filings with the SEC, including our 2005 Annual Report on Form 10-K. This discussion contains forward-looking statements based upon current expectations that involve risk and uncertainties. Our actual results and the timing of certain events could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those set forth below and under “Risk Factors” set forth in Part II, Item 1A of this report and Item 1A and elsewhere in our 2005 Annual Report on Form 10-K.

OVERVIEW

ImClone Systems is a biopharmaceutical company whose mission is to advance oncology care by developing and commercializing a portfolio of targeted treatments designed to address the medical needs of patients with cancer. On February 12, 2004, the FDA approved ERBITUX for use in combination with irinotecan in the treatment of patients with EGFR-expressing, metastatic colorectal cancer who are refractory to irinotecan-based chemotherapy and for use as a single agent in the treatment of patients with EGFR-expressing, metastatic colorectal cancer who are intolerant to irinotecan-based chemotherapy. In September 2005, Health Canada approved the use of ERBITUX for use in combination with irinotecan for the treatment of EGFR-expressing metastatic colorectal carcinoma in patients who are refractory to other irinotecan-based chemotherapy regimens and for use as a single agent for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are intolerant to irinotecan-based chemotherapy. On March 1, 2006, the FDA approved ERBITUX for use in combination with radiation therapy for the treatment of locally or regionally advanced SCCHN and as a single agent in recurrent or metastatic SCCHN where prior platinum-based chemotherapy has failed. Reference full prescribing information, available at www.ERBITUX.com, for important safety information relating to ERBITUX, including boxed warnings.

On December 1, 2003, Swissmedic, the Swiss agency for therapeutic products, approved ERBITUX in Switzerland for the treatment of patients with colorectal cancer who no longer respond to standard chemotherapy treatment with irinotecan. Merck KGaA licensed the right to market ERBITUX outside the United States and Canada from the Company in 1998. In Japan, Merck KGaA has marketing rights to ERBITUX, which are co-exclusive to the co-development rights of the Company and BMS. On June 30, 2004, Merck KGaA received marketing approval by the European Commission to sell ERBITUX for use in combination with irinotecan for the treatment of patients with EGFR-expressing metastatic colorectal cancer after failure of irinotecan including cytotoxic therapy. On December 22, 2005, Swissmedic approved ERBITUX in Switzerland in combination with radiation in the treatment of patients with previously untreated, advanced SCCHN. On April 3, 2006, Merck KGaA was granted marketing authorization by the European Commission to extend the use of ERBITUX, in combination with radiotherapy, to the treatment of patients with locally advanced SCCHN.

Our revenues, as well as our results of operations, have fluctuated and are expected to continue to fluctuate significantly from period to period due to several factors, including but not limited to:

·the amount and timing of revenues earned from commercial sales of ERBITUX;

·the timing of recognition of license fees and milestone revenues;

·the status of development of our various product candidates;

·whether or not we achieve specified research or commercialization objectives;

33

·fluctuations in our effective tax rate and timing on when we may revise our conclusions regarding the realization of our net deferred tax assets, which currently have a partial valuation allowance;

·legal costs and the outcome of outstanding legal proceedings; and

·the addition or termination of research programs or funding support and variations in the level of expenses related to our proprietary product candidates during any given period.

As a result of our substantial investment in research and development, we have incurred significant operating losses and have an accumulated deficit of approximately $176 million as of June 30, 2006. We anticipate that our accumulated deficit will continue to decrease in the future as we earn revenues on commercial sales of ERBITUX and generate net income. Although prior to 2004 we devoted most of our efforts and resources to research and development, we expect that we will continue to devote greater efforts and resources to the manufacturing, marketing, and commercialization of ERBITUX. There is no assurance that we will be able to continue to successfully manufacture, market or commercialize ERBITUX or that potential customers will buy ERBITUX. We rely entirely on third party manufacturers for filling and finishing services with respect to ERBITUX. If our current third party manufacturers or critical raw material suppliers fail to meet our expectations, we cannot be assured that we will be able to enter into new agreements with other suppliers or third party manufacturers without an adverse effect on our business.

HIGHLIGHTS AND OUTLOOK

As previously noted in our 2005 Annual Report on Form 10-K, on January 24, 2006, we announced that our Board of Directors had engaged the investment bank Lazard to conduct, in conjunction with management, a full review of the Company’s strategic alternatives to maximize shareholder value. This review was initiated to ensure that we could benefit from our long-term, high-value investments in the short term, realizing immediate shareholder value while mitigating the impact on profitability associated with the development of ERBITUX and our product candidates. Among the alternatives we may ultimately pursue are a merger, sale or strategic alliance. The process is still ongoing at this point and we will make an announcement as soon as any decisions have been made. It should be noted that while this process is ongoing, we continue to execute a program of focused investment in order to ensure that we sustain our competitive position and that we are adequately positioned for sustainable, longer-term growth. While it is our intention to execute an appropriate transaction, we cannot make assurances that any particular alternative will be pursued or that a transaction will occur. To that end, we will continue to operate in the ordinary course, and we will continue a program of robust investment in the future of our products.

The second quarter of 2006 represented the first full quarter with FDA approval to sell ERBITUX in two tumor types. Domestic in-market sales during the second quarter of 2006 continued to grow, reaching $172.8 million, an increase of 25% over the first quarter of 2006, and an increase of 77% from the second quarter of 2005. This growth is, in large measure, attributable to a rapid uptake of ERBITUX in head and neck cancer since the launch in March 2006. This quarter we were also successful in amending and supplementing our 1998 development and license agreement with our partner, Merck KGaA. Merck and Takeda Pharmaceutical Company signed an alliance in September 2005 for the development and commercialization of matuzumab, a humanized EGFR-targeting monoclonal antibody. As part of the amended agreements between us and Merck KGaA, we have consented to Merck KGaA’s sublicense of certain intellectual property rights relating to the development and commercialization of matuzumab to Takeda Pharmaceutical Company. In consideration for our consent, Merck KGaA agreed to pay us 2.5 million euros upon execution of the agreements and an additional 5 million euros upon our written consent to the sublicense. In addition, Merck KGaA agreed to increase its royalty payment on sales of ERBITUX from a percentage of gross margin to 9.5% of net sales of ERBITUX outside the US and

34

Canada, effective July 1, 2006. This replaces a tiered royalty percentage of gross margin that recently approximated 7.0 to 7.5% of net sales. The amended agreements do not extend to key intellectual property rights in the U.S. and Canada, where we continue to hold exclusive licenses to key patents covering certain uses of EGFR-targeted monoclonal antibodies. The amended agreements also promote freedom to operate in the development and commercialization of matuzumab outside the United States and Canada and of IMC-11F8 (a fully human EGFR-targeted IgG1 monoclonal antibody) within the United States and Canada through the grant of certain reciprocal rights, including the sharing of confidential technical information. These amended agreements mark an important step toward resolving issues relevant to each company’s ongoing development of future generation EGFR-targeted therapies. In addition, they provide us with added financial value from our commercial agreement with Merck KGaA as it relates to ERBITUX.

From an operating perspective, during the second quarter of 2006, our second commercial-scale manufacturing facility, BB50, began commercial production of ERBITUX in anticipation of a registrational filing in early 2007. As previously noted, during the remainder of 2006, we will continue to execute a program of focused investments. The following guidance has been provided on our expected results for 2006:

Royalty revenue in 2006 will continue to reflect 39% of BMS’s net sales and beginning July 1, 2006, 9.5% of Merck KGaA net sales. License fees and milestone revenue in 2006 will include the continuing amortization, based on clinical development spending, of the $900 million received from BMS. At the anticipated rates of clinical spending for 2006, amortization of milestones for the full year should approximate $250 million. Manufacturing revenue in 2006 will continue to reflect ERBITUX shipped to our partners for commercial use. The price charged for commercial material is based on our actual cost to manufacture the product, plus, in the case of BMS only, a 10% mark-up on bulk manufacturing costs. Collaborative agreement revenue in 2006 will continue to include the purchase of ERBITUX for clinical use by our partners, reimbursement by our corporate partners of certain regulatory, clinical and marketing expenses incurred on behalf of ERBITUX, and reimbursement of royalty expenses of 4.5% of North American net sales in accordance with the existing terms of the BMS agreement, as well as a low single digit amount from Merck KGaA.

Effective January 1, 2006, we adopted Financial Accounting Standards Statement No. 123 (revised 2004), Share-Based Payment, which provides that the expense associated with share-based payment transactions be recognized in the financial statements. We estimate that the total expense for stock options in 2006 will be approximately $9.6 million. Compensation expense for the three and six months ended June 30, 2006 amounted to approximately $2.2 million and $4.1 million, respectively and this expense is reflected in each expense category where the employee benefits are categorized. Research and development expenses include costs to support our pre-clinical research efforts as well as development costs (including process scale-up, toxicology and production of non-ERBITUX clinical materials) for our pipeline products. These costs are expected to approximate $130 million in 2006, including approximately $3.1 million attributable to share based compensation expense. The increase from 2005 reflects additional efforts in support of our non-ERBITUX pipeline, including third-party manufacturing costs, costs associated with producing clinical supplies of ERBITUX for use by us and our partners (which are reimbursed as a component of collaborative agreement revenue). Clinical and regulatory expenses in 2006 are expected to increase as we embark on a number of studies in support of expanded use of ERBITUX as well as later-stage clinical development programs for our pipeline products. In addition, we are enhancing our medical affairs programs, and expanding our regulatory capabilities. As a result, total clinical and regulatory expenses are expected to reach approximately $80 million in 2006, including approximately $1.3 million attributable to share based compensation expense. Marketing, general and administrative expenses should approximate $75 million in 2006, including approximately $5.2 million attributable to share based compensation expense. Royalty expense for the remainder of 2006 will consist of

35

approximately 9.25% of North American net sales, with 4.5% of North American net sales expected to be reimbursed by BMS as a component of collaborative agreement revenue, resulting in a net royalty burden to us of 4.75%. In addition, royalty expense at a single-digit percentage of international net sales will also be incurred. Cost of manufacturing revenue for the remainder of 2006 will reflect full absorption costs since we sold all previously expensed inventory. The effective tax rate in 2006 is estimated to be approximately 15%, which excludes the effect of the partial release of our valuation allowance in the first quarter of 2006. The estimated tax rate of 15% increased slightly from our original estimate in the first quarter of 2006 of 13%, due to higher projected income for the full-year 2006 than previously estimated. The most significant reason for the increase in projected taxable income is due to the expected receipt of the up-front payments from Merck KGaA as a result of amending, in July 2006, the 1998 development and license agreement with Merck KGaA.

CRITICAL ACCOUNTING POLICIES

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. We base our estimates on historical experience and on assumptions that we believe to be reasonable under the circumstances. Estimates are deemed critical when a different methodology could have reasonably been used or where changes in the estimate from period to period may have a material impact on our financial condition or results of operations. Our critical accounting policies that require management to make significant judgments, estimates, and assumptions are set forth below. The development and selection of the critical accounting policies, and the related disclosure below, have been reviewed with the Audit Committee of our Board of Directors.

Revenue Recognition—Our revenues are derived from four primary sources: license fees and milestone payments, manufacturing revenue, royalty revenue, and collaborative agreement revenue.

Revenues from license fees and milestone payments primarily consist of up-front license fees and milestone payments received under the Commercial Agreement with BMS, relating to ERBITUX, and milestone payments received under the development and license agreement with Merck KGaA. We recognize all non-refundable up-front license fees as revenues in accordance with the guidance provided in the SEC’s Staff Accounting Bulletin No. 104. Our most critical application of this policy, to date, relates to the $900,000,000 in license fees received from BMS under the Commercial Agreement which are being deferred and recognized as revenue based upon the actual product clinical and development costs incurred since September 19, 2001 to date by BMS and ImClone as a percentage of the estimated total of such costs to be incurred over the 17 year term of the Commercial Agreement. The estimated total of such costs is based on the clinical development budget which establishes joint responsibilities that will be carried out by both the Company and BMS for certain clinical and other studies. Of the $900,000,000 in payments received through June 30, 2006, $33.4 million was recognized as revenue in the second quarter of 2006 and $471.6 million from the commencement of the Commercial Agreement in 2001 through June 30, 2006. The methodology used to recognize deferred revenue involves a number of estimates and judgments, such as the estimate of total product clinical and development costs to be incurred under the Commercial Agreement. Changes in these estimates and judgments can have a significant effect on the size and timing of revenue recognition. In addition, if management had chosen a different methodology to recognize the license fee and milestone payments received under the Commercial Agreement, the Company’s financial position and results of operations could have differed materially. For example, if the Company were to recognize the revenues earned from the Commercial Agreement on a straight-line basis over the life of the agreement, the Company would have recognized approximately $15.9 million and $157.2 million as revenue in the second quarter of 2006 and from the commencement of the Commercial Agreement,

36

respectively, through June 30, 2006. Management believes that the current methodology used to recognize revenues under the Commercial Agreement, which reflects the level of effort consistent with the product development activities, is the most appropriate methodology because it reflects the level of expenditure and activity in the period in which it is being spent as compared to the total expected expenditure over the life of the Commercial Agreement. This cost to cost approach is systematic and rational, it provides a factually supportable pattern to track progress, and is reflective of the level of effort, which varies over time.

Non-refundable upfront payments received from Merck KGaA were deferred due to our significant continuing involvement and are being recognized as revenue on a straight-line basis over the estimated service period because the activities specified in the agreement between the Company and Merck KGaA will be performed over the estimated service period and there is no other pattern or circumstances that indicate a different way in which the revenue is earned. In addition, the development and license agreement with Merck KGaA does not contain any provisions for establishing a clinical budget and none has been established between the parties. This agreement does not call for co-development with the Company in Merck KGaA’s territory; rather Merck KGaA is solely responsible for regulatory efforts in its territory. Non-refundable milestone payments, which represent the achievement of a significant step in the research and development process, pursuant to collaborative agreements other than the Commercial Agreement, are recognized as revenue upon the achievement of the specified milestone. This is because each milestone payment represents the achievement of a substantive step in the research and development process and Merck KGaA has the right to evaluate the technology to decide whether to continue with the research and development program as each milestone is reached.

Manufacturing revenue consists of revenue earned on the sale of ERBITUX to our corporate partners for subsequent commercial sale. The Company recognizes manufacturing revenue when the product is shipped, which is when our partners take ownership and title has passed, collectibility is reasonably assured, the sales price is fixed or determinable, and there is persuasive evidence of an arrangement. We are contractually obligated to sell ERBITUX to BMS at our cost of production plus a 10% markup on bulk. We sell bulk inventory to Merck KGaA at our full absorption cost of production. The continuing level of manufacturing revenue in future periods may fluctuate significantly based on market demand, our cost of production, as well as BMS’s required level of safety stock inventory for ERBITUX and whether Merck KGaA continues to order ERBITUX for commercial use.

Royalty revenues from licensees, which are based on third-party sales of licensed products and technology, are recorded as earned in accordance with contract terms when third-party sales can be reliably measured and collection of funds is reasonably assured.

Collaborative agreement revenue consists of reimbursements received from BMS and Merck KGaA related to clinical and regulatory studies, ERBITUX provided to them for use in clinical studies, reimbursement of a portion of royalty expense and certain marketing and administrative costs. Collaborative agreement revenue is recorded as earned based on the performance requirements under the respective contracts.

Inventories—Until February 12, 2004, all costs associated with the manufacturing of ERBITUX were included in research and development expenses when incurred. Effective February 13, 2004, the date after we received approval from the FDA for ERBITUX, we began to capitalize in inventory the cost of manufacturing ERBITUX and have expensed such costs as cost of manufacturing revenue at the time of sale. Since we had previously expensed all inventory produced, the costs of manufacturing revenue in 2004 reflected minimal costs primarily consisting of shipping and storage charges. In 2005, we continued to sell inventory that was previously expensed and gradually began to sell inventory that was partially expensed, since there was inventory in process on the date that we received FDA approval of ERBITUX. In the fourth quarter of 2005, we sold substantially all inventory with partial costs. As a result, our cost of

37

manufacturing revenue in the remainder of 2006 will reflect full absorption costs of production since the remaining partially expensed inventory was fully recognized in the first quarter of 2006. We expect that our quarterly margins on sales of ERBITUX will therefore begin to stabilize in 2006 and reflect an average margin that will range between 5%- 8% depending on various circumstances such as the level of demand from our partners and the costs of filling and finishing the product (which does not include a markup when selling to BMS), relative to the overall costs of the bulk.

Our policy is to capitalize inventory costs associated with our products when, based on management’s judgment, future economic benefit is expected to be realized. Our accounting policy addresses the attributes that should be considered in evaluating whether the costs to manufacture a product have met the definition of an asset as stipulated in FASB Concepts Statement No. 6. If applicable, we assess the regulatory and approval process including any known constraints and impediments to approval. We also consider the shelf life of the product in relation to the expected timeline for approval. We review our inventory for excess or obsolete inventory and write down obsolete or otherwise unmarketable inventory to its estimated net realizable value.

In June 2006, we began producing ERBITUX for commercial use at our BB50 manufacturing facility. Based on our current timeline, we expect to file a sBLA with the FDA for approval of our BB50 facility in the first quarter of 2007. Until such time as we receive approval of BB50 from the FDA, we will not be able to sell the ERBITUX inventory produced in BB50. Based on management’s current expectations, we expect that the costs of such inventory will be fully realizable once we obtain approval of BB50. Therefore, in June 2006 we began to capitalize the costs of producing ERBITUX in BB50 and will continue to do so, as long as we can conclude that the costs of such inventory will be fully realizable.

During the second quarter of 2006, certain manufacturing improvements were made to the equipment in the Company’s single manufacturing facility that requires regulatory action. The Company plans to file a sBLA with the FDA in the middle of August 2006, and we expect to be able to distribute ERBITUX produced with the improved equipment approximately thirty days after the submission date. As of June 30, 2006, there was approximately $16.2 million of inventory produced using this equipment.

Litigation—The Company is currently involved in certain legal proceedings as disclosed in the notes to the consolidated financial statements. As of June 30, 2006, we have not established a legal reserve in our financial statements because we do not believe that such a reserve is required to be established at this time, in accordance with Statement of Financial Standards No. 5. However, if in a future period, events in any such legal proceedings render it probable that a loss will be incurred, and if such loss is reasonably estimable at that time, we will establish such a reserve. Thus, it is possible that legal proceedings may have a material adverse impact on the operating results for that period, on our balance sheet or both.

Long-Lived Assets—We review long-lived assets for impairment when events or changes in business conditions indicate that their full carrying value may not be recovered. Assets are considered to be impaired and written down to fair value if expected associated undiscounted cash flows are less than carrying amounts. Fair value is generally determined as the present value of the expected associated cash flows. We own a number of buildings that are primarily dedicated to the manufacturing of ERBITUX and other clinical products in our pipeline. Based on management’s current estimates, we expect to recover the carrying value of such assets. Changes in regulatory or other business conditions in the future could change our judgments about the carrying value of these facilities, which could result in the recognition of material impairment losses.

38

Income Taxes—Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Significant estimates are required in determining our provision for income taxes. In the first quarter of 2006, we released a portion of our valuation allowance against our deferred tax assets because we determined, based on revised expectations of our projected future earnings, that it is more likely than not that we will realize the benefit of these deferred tax assets, which amounted to approximately $99.5 million. Our conclusion to release a portion of our valuation allowance against our deferred tax assets is supported by several events that transpired during the first quarter of 2006. In addition to obtaining approval from the FDA for ERBITUX as a second indication in March of 2006, the in-market sales for ERBITUX during this period exceeded our expectations and have continued to show strong growth in the marketplace. Most importantly, a potential competitor released certain clinical data on their competing product, which gave us the ability to further understand the competitive threats posed by this potential product. Therefore, our decision is supported by a combination of better than expected in-market sales that we believe will be sustainable in the future coupled with the ability to further refine our future financial projections and assumptions related to our competition. The financial projections supporting our conclusion to release a portion of our valuation allowance contain significant assumptions based on current facts about our market share and our competitive landscape. If such assumptions were to differ significantly, it may have a material impact on our ability to realize our deferred tax assets.

Impact of Recent Accounting Pronouncements

In June 2006, the Financial Accounting Standards Board (“FASB”) issued FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes—an interpretation of FASB Statement No. 109. This Interpretation clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements in accordance with FASB No. 109, Accounting for Income Taxes. It also prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. This Interpretation also provides guidance on derecognition, classification of interest and penalties, accounting in interim periods, disclosure, and transition. This Interpretation is effective for fiscal years beginning after December 15, 2006. We are in the process of analyzing the impact that this Interpretation may have on our consolidated financial statements. Therefore, we are not in a position to conclude whether the adoption of this Interpretation will have a material impact on our financial statements.

39

RESULTS OF OPERATIONS

Selected financial and operating data for the three and six months ended June 30, 2006 and 2005 are as follows: (in thousands)

	Three Months Ended June 30					Six Months Ended June 30
	2006		2005	Variance		2006	2005		Variance
Results of Operations:
Royalty revenue	$	74,614	$41,791	32,823		$134,884	$	78,163	56,721
License fees and milestone revenue	33,456		24,491	8,965		177,859	49,025		128,834
Manufacturing revenue	28,356		7,894	20,462		47,705	18,913		28,792
Collaborative agreement revenue	13,430		18,209	(4,779	)	34,539	32,055		2,484
Total revenues	149,856		92,385	57,471		394,987	178,156		216,831
Research and development	27,583		24,433	3,150		60,576	45,606		14,970
Clinical and regulatory	14,929		8,376	6,553		30,010	17,774		12,236
Marketing, general and administrative	22,963		16,833	6,130		40,964	34,456		6,508
Royalty expense	18,414		14,338	4,076		38,480	26,904		11,576
Cost of manufacturing revenue	26,877		1,106	25,771		42,279	1,849		40,430
Discontinuation of small molecule research program	—		6,200	(6,200	)	—	6,200		(6,200	)
Total operating expenses	110,766		71,286	39,480		212,309	132,789		79,520
Operating income	39,090		21,099	17,991		182,678	45,367		137,311

Three Months Ended June 30, 2006 and 2005

Revenues

Royalty Revenue

Royalty revenue consists primarily of royalty payments earned on the sales of ERBITUX by our partners, BMS and Merck KGaA. Under our agreement with BMS, we are entitled to royalty payments equal to 39% of BMS’s net sales of ERBITUX in the United States and Canada. Under our agreement with Merck KGaA we were entitled to royalty based on a percentage of gross margin of Merck KGaA’s sales of ERBITUX outside the United States and Canada. Beginning in July of 2006, we are entitled to 9.5% of Merck’s KGaA’s net sales outside of the United States and Canada. In the second quarter of 2006, our royalty revenue increased by approximately $32.8 million from the comparable period in 2005 due to an increase in net sales of ERBITUX. In North America, net sales by BMS in the second quarter of 2006 amounted to $172.8 million compared to net sales in the comparable period in 2005 of $97.8 million, an increase of $75 million, or 77%. Outside of North America, net sales of ERBITUX by Merck KGaA in the second quarter of 2006 amounted to approximately $102.5 million, an increase of $40.6 million or 66% from the comparable period in 2005.

Royalty revenue for the second half of 2006 will reflect 39% of BMS’ net sales and 9.5% of Merck KGaA’s net sales.

License Fees and Milestone Revenue

License fees and milestone revenue in the second quarter of 2006 of $33.5 million consists of the recognition of up-front license fees and milestone payments received under the Commercial Agreement

40

with BMS of $33.4 million and recognition of payments received under the development and license agreements with Merck KGaA of $55,000. The increase of $9.0 million, or 37% from the comparable period in 2005, is due to an increase in the clinical development spend as well as the higher amount of deferred revenue being amortized as the result of the receipt of the $250 million milestone from BMS in the first quarter of 2006.

License fees and milestone revenue in 2006 will include the continuing amortization, based on the actual clinical development spending, of the $900 million received from BMS. At the anticipated rates of clinical spending for 2006, amortization of milestones for the full year of 2006 should approximate $250 million.

Manufacturing Revenue

Manufacturing revenue in the second quarter of 2006 of $28.4 million consists of sales of ERBITUX to BMS and Merck KGaA for commercial use. The increase from the comparable period in 2005 of $20.5 million is due to an increase in sales to BMS of approximately $19.7 million and sales to Merck KGaA of $0.8 million. The increase in sales of ERBITUX to our partners for commercial use is directly associated with the increase in in-market sales (as described above under royalty revenue) both in North America and internationally. In accordance with the Commercial Agreement, we sell ERBITUX to BMS at our cost of production plus a 10% markup on bulk. We sell bulk inventory to Merck KGaA at our full absorption cost of production.

Manufacturing revenue in 2006 will continue to reflect ERBITUX shipped to our partners for commercial use.

Collaborative Agreement Revenue

Collaborative agreement revenue consists primarily of reimbursements from our partners BMS and Merck KGaA under our collaborative agreements. There are certain categories for which we receive reimbursement from our partners: clinical and regulatory expenses, the cost of ERBITUX supplied to our partners for use in clinical studies, certain marketing and administrative expenses, and a portion of royalty expense. During the second quarter of 2006, we earned $13.4 million in collaborative agreement revenue, of which approximately $11.8 million represents amounts earned from BMS and approximately $1.6 million represents amounts earned from Merck KGaA, as compared to $18.2 million earned in the comparable period in 2005, of which $11.5 million was earned from BMS and approximately $6.7 million was earned from Merck KGaA. The decrease in collaborative agreement revenue of $4.8 million is principally due to a decrease in reimbursement for clinical drugs of approximately $7.7 million, and a decrease in reimbursement of clinical and marketing and general administrative expenses of approximately $1.2 million, partially offset by an increase in royalty expense reimbursement of approximately $4.1 million as a result of higher sales by our partners.

Collaborative agreement revenue in 2006 will continue to include reimbursements from our corporate partners for: the purchase of ERBITUX for clinical use, certain regulatory, clinical and marketing expenses incurred on behalf of ERBITUX, and for royalty expense of 4.5% of North American net sales in accordance with the existing terms of the BMS agreement and a low single digit amount from Merck KGaA.

Expenses

Research and Development

Research and development expenses in the second quarter of 2006 of $27.6 million increased by approximately $3.2 million, or 13% from the comparable period in 2005. The increase is primarily due to

41

an increase in third party costs associated with the development of our non-ERBITUX pipeline of approximately $4.0 million, an increase in share based compensation of approximately $500,000 and an increase in depreciation expense of $2.7 million, related to our BB50 manufacturing facility that became operational in June 2006. It is our policy that assets placed into service prior to July 1st receive a full year of depreciation. Since BB50 became operational in June of 2006, we reflected six months of depreciation expense in the second quarter of 2006. These increases were partially offset by a decrease in shipments of ERBITUX to our partners for clinical studies of approximately $1.8 million, a decrease in repair and maintenance expenses of approximately $1.0 million and additional decreases in a number of other categories such as relocation expense, and postage and delivery expenses. Research and development expenses include costs associated with our in-house and collaborative research programs, product and process development expenses, cost to manufacture our product candidates and quality assurance and quality control costs. Research and development includes costs that are reimbursable from our corporate partners. Approximately $1.1 million and $8.9 million of costs representing research and development expenses in the second quarters of 2006 and 2005, respectively, were reimbursable and included under collaborative agreement revenue since they represent inventory supplied to our partners for use in clinical studies.

We expect that research and development expenses will approximate $130 million in 2006, including approximately $3.1 million attributable to share based compensation expense. The increase from 2005 reflects additional efforts in support of our non-ERBITUX pipeline, including third-party manufacturing costs, costs associated with clinical supplies of ERBITUX for use by us and our partners (which are reimbursed as a component of collaborative agreement revenue).

Clinical and Regulatory

Clinical and regulatory expenses consist of costs to conduct our clinical studies and associated regulatory activities. Clinical and regulatory expenses in the second quarter of 2006 amounted to $14.9 million, an increase of $6.6 million or 78% from the comparable period in 2005. The increase is primarily due to an increase of $4.4 million due BMS for reimbursement of clinical expenses related to ERBITUX and an increase in salaries and benefits of approximately $1.1 million, which includes $351,000 of share based compensation expense. During 2005, we gradually increased the headcount in our clinical and regulatory department in order to support the continued growth of ERBITUX and to develop other product candidates. Approximately $2.8 million and $3.8 million of the costs included in this category for the second quarters of 2006 and 2005, respectively, are reflected as revenues under collaborative agreement revenue since they represent costs that are reimbursable by our corporate partners.

Clinical and regulatory expenses in 2006 are expected to increase as we embark on a number of studies in support of expanded use of ERBITUX as well as later-stage clinical development programs for our pipeline products. In addition, we are enhancing our medical affairs programs, and expanding our regulatory capabilities. As a result, total clinical and regulatory expenses are expected to reach approximately $80 million in 2006, including approximately $1.3 million attributable to share based compensation expense. A contractually determined portion of the ERBITUX-related expenses will continue to be reimbursed as a component of collaborative agreement revenue.

Marketing, General and Administrative

Marketing, general and administrative expenses include marketing and administrative personnel costs, including related facility costs, additional costs to develop internal marketing and field operations capabilities and expenses associated with applying for patent protection for our technology and products. Marketing, general and administrative expenses also include amounts reimbursable from our corporate partners.

42

Marketing, general and administrative expenses in the second quarter of 2006 amounted to $23.0 million as compared to $16.8 million in the comparable period in 2005, an increase of $6.1 million or 36%. The increase in the second quarter of 2006 is mainly due to an increase in bonus to the field force of $2.4 million, which is directly correlated to the increase in ERBITUX in-market net sales for the quarter, an increase in marketing expenses associated with the launch of ERBITUX for use in head and neck cancer (approved by the FDA in March 2006) of approximately $1.1 million, and $1.4 million of share based compensation expense. Except for the above, expenses in this category have remained fairly stable from the comparable period in 2005, mainly due to having no increases in headcount and spending consistently in legal, accounting and consulting expenses. Certain expenses in this category are reimbursable from our corporate partners. Approximately $336,000 and $544,000 of costs representing marketing and general expenses in the second quarters of 2006 and 2005, respectively, were reimbursable and included in collaborative agreement revenue. Marketing, general and administrative expenses should approximate $75 million in 2006, including approximately $5.2 million attributable to share based compensation expense. The increase versus 2005 is principally attributable to increased marketing efforts in support of launching ERBITUX as a second indication and to shared based compensation expense.

Royalty Expense

Royalty expense consists of obligations related to certain licensing agreements related to ERBITUX. We are obligated to pay royalties of approximately 9.25% of North American net sales and a single digit royalty on sales outside of North America, which will increase if sales outside of North America consist of ERBITUX produced in the United States. We receive reimbursements from our corporate partners of 4.5% on North American net sales and a single digit percentage on net sales outside of North America, which is reflected in collaborative agreement revenue. In the second quarter of 2006, we incurred royalty expense of $18.4 million as compared to $14.3 million, an increase of $4.1 million, or 29%. The increase is directly associated with the increase in net sales of ERBITUX in North America and outside of North America, as previously described. Approximately $9.2 million and $5.0 million of royalty expense were reimbursable by our corporate partners and included as collaborative agreement revenue in the second quarters of 2006 and 2005, respectively.

Royalty expenses for the remainder of 2006 will consists of approximately 9.25% of North American net sales with 4.5% of North American net sales expected to be reimbursed as a component of collaborative agreement revenue, resulting in a net royalty burden of approximately 4.75%. In addition, a single-digit percentage of international net sales is also expected to be incurred.

Cost of Manufacturing Revenue

Cost of manufacturing revenue in the second quarter of 2006 amounted to $26.9 million representing a gross margin of approximately 5% compared to costs of manufacturing revenue in the comparable period of 2005 of approximately $1.1 million, or a gross margin of 86%. The fluctuation in our gross margin is due to the fact that prior to obtaining approval from the FDA for ERBITUX, we had previously expensed all ERBITUX inventory produced as research and development expense. We began to capitalize in inventory the cost of manufacturing ERBITUX after we received approval in February of 2004. It has taken us two years to sell all inventory that was previously expensed or partially expensed. In the first quarter of 2006, we exhausted the remaining batches of ERBITUX with partial costs and we expect our margins to normalize going forward. We sell ERBITUX to BMS at our costs of production plus a 10% mark-up on bulk and to Merck KGaA at our cost of production. Therefore, depending on certain circumstances, such as the mix of demand from our partners, and the costs of filling and finishing ERBITUX bulk (for which we do not charge a 10% markup when selling to BMS), we expect that our quarterly margins on sales of ERBITUX will reflect a gross margin that will range between 5%-8%.

43

Interest Income and Interest Expense

Interest income in the second quarter of 2006 amounted to $10.2 million, an increase of approximately $3.4 million or 50% from the comparable period in 2005. This increase is attributable to increases in interest rates from the comparable period in 2005, and an increase in the average balance of our investment portfolio, which increased in the second quarter, due to the fact that we invested the majority of the $250 million received from BMS in March of 2006.

Interest expense in the second quarter of 2006 amounted to $1.9 million, an increase of $227,000 or 13% from the comparable period in 2005. The increase is due to the fact that we finalized construction of our BB50 manufacturing facility in May of 2006, and therefore, ceased capitalizing interest on the construction of this facility.

Provision for Income Taxes

The estimated effective tax rate used in calculating the full year 2006 is approximately 15% which excludes the effect of a partial release of our valuation allowance. The estimated effective tax rate used for the first quarter of 2006 was 13%; as a result, our effective tax rate for the second quarter of 2006 is 21%. The estimates for the quarter and full-year rates are higher than the Company’s previous estimate of 13% due to higher projected income for the full-year 2006 than previously estimated with no additional operating tax attributes to utilize. The most significant reason for the increase in projected taxable income is due to the expected receipt of the up-front payments from Merck KGaA as a result of amending, in July 2006, the 1998 development and license agreement with Merck KGaA. The projected tax rate for 2006 is less than the federal statutory rate of 35%, mainly due to the utilization of fully reserved deferred tax assets.

Net Income

We had net income of $37.2 million or $0.44 per basic common share and $0.42 per diluted common share in the second quarter of 2006, compared with net income of $26.0 million or $0.31 per basic common share and $0.30 per diluted common share for the comparable period in 2005. The fluctuation in results was due to the factors noted above.

Six Months Ended June 30, 2006 and 2005

Revenues

Royalty Revenue

Royalty revenue consists primarily of royalty payments earned on the sales of ERBITUX by our partners, BMS and Merck KGaA. Under our agreement with BMS, we are entitled to royalty payments equal to 39% of BMS’s net sales of ERBITUX in the United States and Canada. Under our agreement with Merck KGaA we were entitled to royalty based on a percentage of gross margin of Merck KGaA’s sales of ERBITUX outside the United States and Canada. Beginning in July of 2006, we are entitled to 9.5% of Merck’s KGaA’s net sales outside of the United States and Canada. For the six months ended June 30, 2006, royalty revenue amounted to $134.9 million, an increase of $56.7 million or 73% from the comparable period in 2005 due to an increase in net sales of ERBITUX. In North America, net sales by BMS for the first six months of 2006 amounted to $310.8 million compared to net sales in the comparable period in 2005 of $184.9 million, an increase of $125.9 million, or 68%. Outside of North America, net sales of ERBITUX by Merck KGaA in the first half of 2006 amounted to $192.3 million, an increase of $75.6 million or 65% from the comparable period in 2005.

Royalty revenue for the remainder of 2006 will reflect 39% of BMS’ net sales and 9.5% of Merck KGaA’s net sales.

44

License Fees and Milestone Revenue

License fees and milestone revenue for the six months ended June 30, 2006 of $177.9 million consists of the recognition of up-front license fees and milestone payments received under the Commercial Agreement with BMS of $177.7 million and recognition of payments received under the development and license agreements with Merck KGaA of $111,000. The increase of $128.8 million from the comparable period in 2005 is mainly due to the fact that in March 2006, we earned the last milestone payment from BMS of $250 million, as a result of obtaining approval from the FDA for ERBITUX in a second indication. The milestone earned in the first quarter of 2006 therefore includes a “catch-up” adjustment of approximately $112.7 million related to the actual product clinical development costs incurred from inception through December 31, 2005 as a percentage of the estimated total costs to be incurred over the term of the Commercial Agreement.

License fees and milestone revenue in 2006 will include the continuing amortization, based on the clinical development spending, of the $900 million received from BMS. At the anticipated rates of clinical spend for 2006, amortization of milestones for the full year of 2006 should approximate $250 million.

Manufacturing Revenue

Manufacturing revenue for the six months ended June 30, 2006 of $47.7 million consists of sales of ERBITUX to BMS and Merck KGaA for commercial use. The increase from the comparable period in 2005 of $28.8 million is due to an increase in sales to BMS of approximately $25.3 million and sales to Merck KGaA of $3.5 million. The increase in sales of ERBITUX to our partners for commercial use is directly associated with the increase in in-market sales (as described above under royalty revenue) both in North America and internationally. In accordance with the Commercial Agreement, we sell ERBITUX to BMS at our cost of production plus a 10% markup on bulk. We sell bulk inventory to Merck KGaA at our full absorption cost of production.

Manufacturing revenue in 2006 will continue to reflect ERBITUX shipped to our partners for commercial use.

Collaborative Agreement Revenue

Collaborative agreement revenue consists primarily of reimbursements from our partners BMS and Merck KGaA under our collaborative agreements. There are certain categories for which we receive reimbursement from our partners: clinical and regulatory expenses, the cost of ERBITUX supplied to our partners for use in clinical studies, certain marketing and administrative expenses, and a portion of royalty expense. During the six months ended June 30, 2006, we earned $34.5 million in collaborative agreement revenue, of which approximately $25.1 million represents amounts earned from BMS and approximately $9.5 million represents amounts earned from Merck KGaA, as compared to $32.1 million earned in the comparable period in 2005, of which $21.1 million was earned from BMS and approximately $10.9 million was earned from Merck KGaA. The increase in collaborative agreement revenue of $2.5 million is principally due to an increase in reimbursement for royalty expense of $8.2 million, as a result of higher sales by our partners, partially offset by a decrease in reimbursement for clinical drugs of approximately $3.5 million and in the reimbursement of clinical and marketing, general and administrative expenses of approximately $2.2 million.

Collaborative agreement revenue in 2006 will continue to include the purchase of ERBITUX for clinical use by our partners, reimbursement by our corporate partners of certain regulatory, clinical and marketing expenses incurred on behalf of ERBITUX, and for royalty expense of 4.5% of North American net sales in accordance with the existing terms of the BMS agreement and a low single digit amount from Merck KGaA.

45

Expenses

Research and Development

Research and development expenses for the six months ended June 30, 2006 of $60.6 million increased by approximately $15.0 million or 33% from the comparable period in 2005. The increase is primarily due to an increase in third party costs associated with the development of our non-ERBITUX pipeline of approximately $6.7 million, an increase in shipments of ERBITUX sold to our partners for clinical studies of approximately $5.8 million, an increase in shared based compensation of approximately $1.0 million, and an increase in depreciation expense of $2.7 million, related to our BB50 manufacturing facility that became operational in June 2006. It is our policy that assets placed into service prior to July 1st receive a full year depreciation. Since BB50 became operational in June of 2006, we reflected six months of depreciation expense in the second quarter of 2006. These increases were partially offset by decreases in several categories such as repair and maintenance, relocation expenses, and postage and delivery expenses. Research and development expenses include costs associated with our in-house and collaborative research programs, product and process development expenses, cost to manufacture our product candidates and quality assurance and quality control costs. Research and development includes costs that are reimbursable from our corporate partners. Approximately $9.9 million and $13.5 million of costs representing research and development expenses in the first half of 2006 and 2005, respectively, were reimbursable and included under collaborative agreement revenue since they represent inventory supplied to our partners for use in clinical studies.

We expect that research and development expenses will approximate $130 million in 2006, including approximately $3.1 million attributable to share based compensation expense. The increase from 2005 reflects additional efforts in support of our non-ERBITUX pipeline, including third-party manufacturing costs, costs associated with clinical supplies of ERBITUX (which are reimbursed as a component of collaborative agreement revenue).

Clinical and Regulatory

Clinical and regulatory expenses consist of costs to conduct our clinical studies and associated regulatory activities. Clinical and regulatory expenses for the six months ended June 30, 2006 amounted to $30.0 million, an increase of $12.2 million or 69% from the comparable period in 2005. The increase is primarily due to an increase of $8.5 million due BMS for reimbursement of clinical expenses related to ERBITUX and an increase in salaries and benefits of approximately $2.1 million, which includes $669,000 of share based compensation expense. During 2005, we gradually increased our headcount in our clinical and regulatory department in order to invest in the continued growth of ERBITUX and to develop other product candidates. Approximately $6.2 million and $7.9 million of the costs included in this category for the first half of 2006 and 2005, respectively, are reflected as revenues under collaborative agreement revenue since they represent costs that are reimbursable by our corporate partners.

Clinical and regulatory expenses in 2006 are expected to increase as we embark on a number of studies in support of expanded use of ERBITUX as well as later-stage clinical development programs for our pipeline products. In addition, we are enhancing our medical affairs programs, and expanding our regulatory capabilities. As a result, total clinical and regulatory expenses are expected to reach approximately $80 million in 2006, including approximately $1.3 million attributable to share based compensation expense. A contractually determined portion of the ERBITUX-related expenses will continue to be reimbursed as a component of collaborative agreement revenue.

Marketing, General and Administrative

Marketing, general and administrative expenses include marketing and administrative personnel costs, including related facility costs, additional costs to develop internal marketing and field operations

46

capabilities and expenses associated with applying for patent protection for our technology and products. Marketing, general and administrative expenses also include amounts reimbursable from our corporate partners.

Marketing, general and administrative expenses for the six months ended June 30, 2006 amounted to $40.9 million, an increase of $6.5 million or 19% from the comparable period in 2005. The increase is mainly due to an increase in bonus to the field force of $2.4 million, which is directly correlated to the increase in ERBITUX in-market net sales, an increase in marketing expenses associated with the launch of ERBITUX for use in head and neck cancer (approved by the FDA in March 2006) of approximately $1.2 million, and $2.4 million of shared based compensation expense. The remaining expenses in this category have remained fairly stable from the comparable period in 2005, mainly due to having no increases in headcount and spending consistently in legal, accounting and consulting expenses. Certain expenses in this category are reimbursable from our corporate partners. Approximately $650,000 and $1.1 million of costs representing marketing and general expenses for the six months ended June 30, 2006 and 2005, respectively, were reimbursable and included in collaborative agreement revenue. Marketing, general and administrative expenses should approximate $75 million in 2006, including approximately $5.2 million attributable to share based compensation expense. The increase versus 2005 is principally attributable to increased marketing efforts in support of launching ERBITUX as a second indication.

Royalty Expense

Royalty expense consists of obligations related to certain licensing agreements related to ERBITUX. We are obligated to pay royalties of approximately 9.25% of North American net sales and a single digit royalty on sales outside of North America, which will increase if sales outside of North America consist of ERBITUX produced in the United States. We receive reimbursements from our corporate partners of 4.5% on North American net sales and a single digit percentage on net sales outside of North America, which is reflected in collaborative agreement revenue. During the six months ended June 30, 2006, we incurred royalty expense of $38.5 million as compared to $26.9 million, an increase of $11.6 million, or 43%. The increase is directly associated with the increase in net sales of ERBITUX in North America and outside of North America, as previously described. Approximately $17.8 million and $9.5 million of royalty expense was reimbursable by our corporate partners and included as collaborative agreement revenue in the first half of 2006 and 2005, respectively.

Royalty expenses for the remainder of 2006 will consists of approximately 9.25% of North American in-market net sales with 4.5% of North American net sales expected to be reimbursed as a component of collaborative agreement revenue, resulting in a net royalty burden of approximately 4.75%. In addition, a single-digit percentage of international net sales is also expected to be incurred.

Cost of Manufacturing Revenue

Cost of manufacturing revenue for the six months ended June 30, 2006 amounted to $42.3 million representing a gross margin of approximately 11% compared to costs of manufacturing revenue in the comparable period of 2005 of approximately $1.8 million, or a gross margin of 90%. The fluctuation in our gross margin is due to the fact that prior to obtaining approval from the FDA for ERBITUX, we had previously expensed all ERBITUX inventory produced as research and development. We began to capitalize in inventory the cost of manufacturing ERBITUX after we received approval in February of 2004. It has taken us two years to sell all inventory that was previously expensed or partially expensed. In the first quarter of 2006, we exhausted the remaining batches of ERBITUX with partial costs and we expect our margins to normalize going forward. We sell ERBITUX to BMS at our costs of production plus a 10% mark-up on bulk and to Merck KGaA at our cost of production. Therefore, depending on certain circumstance such as the mix of demand from our partners, and the costs of filling and finishing

47

ERBITUX bulk (for which we do not charge a 10% markup when selling to BMS), we expect that our quarterly margins on sales of ERBITUX will reflect a gross margin that will range between 5%-8%.

Interest Income and Interest Expense

Interest income for the six months ended June 30, 2006 amounted to $17.4 million, an increase of approximately $3.8 million or 28% from the comparable period in 2005. This increase is attributable to increases in interest rates from the comparable period in 2005, and an increase in the average balance of our investment portfolio, which increased in the second quarter, due to the fact that we invested the majority of the $250 million received from BMS in March of 2006.

Interest expense for the six months ended June 30, 2006 amounted to $3.4 million, which is consistent with the comparable period in 2005.

Provision for Income Taxes

The Company’s estimated annual effective income tax rate for 2006 is approximately 15% which excludes the effect of the partial release of our valuation allowance described below. The estimate for the full-year rates is higher than the Company’s previous estimate of 13% due to higher projected income for the full-year 2006 than previously estimated with no additional operating tax attributes to utilize. The most significant reason for the increase in projected taxable income is due to the expected receipt of the up-front payments from Merck KGaA as a result of amending, in July 2006, the 1998 development and license agreement with Merck KGaA. The projected tax rate for 2006 is less than the federal statutory rate of 35%, mainly due to the utilization of fully reserved deferred tax assets.

In the first quarter of 2006, we released a portion of its valuation allowance against our total deferred tax assets because we determined, based on revised expectations of our projected future earnings, that it is more likely than not that we will realize the benefit of these deferred tax assets, which amounted to approximately $99.5 million. Our conclusion to release a portion of our valuation allowance against our deferred tax assets is supported by several events that transpired during the first quarter of 2006. In addition to obtaining approval from the FDA for ERBITUX in a second indication in March of 2006, the in-market sales for ERBITUX during this period exceeded our expectations and have continued to show strong growth in the marketplace. Most importantly, a potential competitor released certain clinical data on their competing product, which gave us the ability to further understand the competitive threats posed by this potential product. Therefore, our decision is supported by a combination of better than expected in-market sales that we believe will be sustainable in the future coupled with the ability to further refine our future financial projections and assumptions related to our competition. The financial projections supporting our conclusion to release a portion of our valuation allowance contain significant assumptions based on current facts about our market share and our competitive landscape. If such assumptions were to differ significantly, it may have a material impact on our ability to realize our deferred tax assets.

Net Income

We had net income of $266.8 million or $3.18 per basic common share and $2.93 per diluted common share for the six months ended June 30, 2006, compared with net income of $54.9 million or $0.66 per basic common share and $0.63 per diluted common share for the comparable period in 2005. The fluctuation in results was due to the factors noted above.

LIQUIDITY AND CAPITAL RESOURCES

At June 30, 2006, our principal sources of liquidity consisted of cash and cash equivalents and securities available for sale of approximately $963.8 million. Historically, we have financed our operations through a variety of sources, most significantly through the issuance of public and private equity and

48

convertible notes, license fees and milestone payments and reimbursements from our corporate partners. Since the approval of ERBITUX on February 12, 2004, we began to generate royalty revenue and manufacturing revenue from the commercial sale of ERBITUX by our corporate partners and we have generated income from operations in 2004, 2005 and in the first half of 2006. As we continue to generate income, our cash flows from operating activities are expected to increase as a source to fund our operations. Therefore, we anticipate that our future financial condition and our future operating performance will continue to experience significant changes and that past performance will not likely be indicative of our future performance.

SUMMARY OF CASH FLOWS

	June 30, 2006			June 30, 2005			Variance
Cash provided by (used) in:
Operating activities	$	180,308		$	(64,968	)	$	245,276
Investing activities	(219,164		)	(22,133		)	(197,031		)
Financing activities	61,548			12,368			49,180
Net increase (decrease) in cash and cash equivalents	$	22,692		$	(74,733	)	$	97,425

Historically our cash flows from operating activities have fluctuated significantly due to the nature of our operations and the timing of our cash receipts. During the first half of 2006, we generated approximately $180.3 million in cash from operating activities, as compared to net cash used in operating activities in the comparable period of 2005 of $65 million. The increase in operating cash flows in the first half of 2006 is primarily due to the receipt of $250 million milestone payment from our corporate partner BMS, as a result of obtaining approval from the FDA for ERBITUX in a second indication, partly offset by a payment to the IRS of approximately $32 million for withholding taxes related to an employment tax audit for the years 1999-2001.

Our primary sources and uses of cash from investing activities consist of purchases and sales activity in our investment portfolio, which we manage based on our liquidity needs, possible business development transactions and amounts used for capital expenditures. During the first half of 2006, we used net cash from investing activities of $219.2 million comprised of approximately $32.5 million in acquisition of fixed assets, and we made net purchases of securities of approximately $186.7 million by investing the majority of the milestone payment received from BMS at the end of the first quarter of 2006.

We generated net cash flows from financing activities in the first half of 2006 of approximately $61.5 million as compared to $12.4 million in the comparable period of 2005. Cash flows from financing activities were generated from employees exercising stock options and from the issuance of common stock under our employee stock purchase plan. In addition, this category reflects the benefit of equity net operating losses that will be taken as a reduction in our tax liability on our tax return and therefore, saving us cash by reducing our federal and state taxes due.

49

Below is a table that presents our contractual obligations and commercial commitments as of June 30, 2006: (in thousands)

	Payments due by Year(1)
	Total		2006		2007		2008		2009		2010		2011 and Thereafter
Long-term debt(2)	$	600,000	$	—	$	—	$	—	$	—	$	—	$	600,000
Interest on long-term debt	147,469		4,125		8,250		8,250		8,250		8,250		110,344
Operating leases	68,473		2,410		5,385		4,227		4,263		4,174		48,014
Purchase obligations	8,449		8,449		—		—		—		—		—
Contract services obligations	19,800		10,080		3,510		1,350		1,620		3,240		—
Total contractual cash obligations	$	844,191	$	25,064	$	17,145	$	13,827	$	14,133	$	15,664	$	758,358

(1)Amounts in the above table do not include milestone-type payments payable by us under collaborative agreements.

(2)On May 15, 2009, 2014 and 2019, or upon the occurrence of certain designated events, holders may require the Company to repurchase the notes at a repurchase price equal to 100% of the principal amount of the notes plus accrued and unpaid interest.

OFF-BALANCE SHEET ARRANGEMENTS

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, results of operations, liquidity, capital expenditures or capital resources.

Item 3.Quantitative and Qualitative Disclosures About Market Risk

Our holdings of financial instruments comprise a mix of U.S. dollar denominated securities that may include U.S. corporate debt, foreign corporate debt, U.S. government debt, foreign government debt, asset-backed securities, agency debt and commercial paper. All such instruments are classified as securities available for sale. Generally, we do not invest in portfolio equity securities, commodities, foreign exchange contracts or use financial derivatives for trading purposes. Our debt security portfolio represents funds held temporarily pending use in our business and operations. We manage these funds accordingly. We seek reasonable assuredness of the safety of principal and market liquidity by investing in investment grade fixed income securities while at the same time seeking to achieve a favorable rate of return. Our market risk exposure consists principally of exposure to changes in interest rates. Our holdings are also exposed to the risks of changes in the credit quality of issuers. We invest in securities that have a range of maturity dates.

50

The table below presents the principal amounts and related weighted average interest rates by year of maturity for our investment portfolio as of June 30, 2006: (in thousands, except interest rates)

	2006			2007			2008			2009			2010			2011 and Thereafter				Total			Fair Value
Fixed Rate	$	150,000		$	212,400		$	100,000		$	55,000		$	20,000			$	—		$	537,400		$	526,506
Average Interest Rate	2.97		%	3.51		%	3.86		%	4.33		%	4.54		%		—			3.55		%
Variable Rate(1)	—			—			1,803			—			10,000				399,625			411,428			411,178
Average Interest Rate	—			—			4.85		%	—			4.00		%		5.25		%	5.22		%
	$	150,000		$	212,400		$	101,803		$	55,000		$	30,000			$	399,625		$	948,828		$	937,684

(1)These holdings primarily consist of U.S. corporate and foreign corporate floating rate notes. Interest on the securities is adjusted monthly, quarterly or semi-annually, depending on the instrument, using prevailing interest rates. These holdings are highly liquid and we consider the potential for loss of principal to be minimal.

Our outstanding 13¤8% fixed rate convertible senior notes in the principal amount of $600,000,000 due May 15, 2024 are convertible into our common stock at a conversion price of $94.69 per share, subject to certain restrictions as outlined in the indenture agreement. The fair value of fixed interest rate instruments is affected by changes in interest rates and in the case of the convertible notes by changes in the price of our common stock as well. The fair value of the convertible senior notes was approximately $541,500,000 at June 30, 2006.

Item 4.Controls and Procedures

Disclosure Controls and Procedures

Our management, with the participation of our Interim Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our “disclosure controls and procedures” (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this report. Based on such evaluation, our Interim Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in recording, processing, summarizing and reporting, on a timely basis, information that we are required to disclose in the reports that we file or submit under the Exchange Act.

Changes In Internal Control Over Financial Reporting

There has been no change in our internal control over financial reporting during the three months ended June 30, 2006 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

51

PART II

OTHER INFORMATION

Item 1.Legal Proceedings

A.   Government Inquiries and Investigations

In January 2003, New York State notified the Company that the Company was liable for the New York State and City income taxes that were not withheld because one or more the Company’s employees who exercised certain non-qualified stock options in 1999 and 2000 failed to pay New York State and City income taxes for those years. On March 13, 2003, the Company entered into a closing agreement with New York State, paying $4,500,000 to settle the matter. The Company believes that substantially all of the underpayment of New York State and City income tax identified by New York State is attributable to the exercise of non-qualified stock options by the Company’s former President and Chief Executive Officer, Dr. Samuel D. Waksal. At the same time, the Company informed the IRS, the SEC and the United States Attorney’s Office, responsible for the prosecution of Dr. Samuel D. Waksal, of this issue. In order to confirm whether the Company’s liability in this regard was limited to Dr. Samuel D. Waksal’s failure to pay income taxes, the Company contacted current and former officers and employees who had exercised non-qualified stock options to confirm that those individuals had properly reported and paid their personal income tax liabilities for the years 1999 and 2000 in which they exercised options, which would reduce or eliminate the Company’s potential liability for failure to withhold income taxes on the exercise of those options. In the course of doing so, the Company became aware of another potential income and employment tax withholding liability associated with the exercise of certain warrants granted in the early years of the Company’s existence that were held by certain former officers, directors and employees, including the Company’s former President and Chief Executive Officer, Samuel D. Waksal, the Company’s former General Counsel, John B. Landes, the Company’s former Chief Scientific Officer, Harlan W. Waksal, and the Company’s former director and Chairman of the Board, Robert F. Goldhammer. Again, the Company promptly informed the IRS, the SEC and the United States Attorney’s Office of this issue. The Company also informed New York State of this issue. On June 17, 2003, New York State notified the Company that based on this issue, they were continuing a previously conducted audit and were evaluating the terms of the closing agreement to determine whether it should be re-opened. On March 31, 2004, the Company entered into a new closing agreement pursuant to which the Company paid New York State an additional $1,000,000 in full satisfaction of all the deficiencies and determinations of withholding taxes for the years 1999-2001. Therefore, the Company has eliminated the liability of $2,815,000, which was accrued as of December 31, 2003, primarily attributable to New York State withholding taxes on stock options and warrants exercised by Dr. Samuel D. Waksal and has recognized a benefit of $1,815,000 as a recovery in the Consolidated Statements of Operations in the first quarter of 2004.

On March 31, 2003, the Company received notification from the SEC that it was conducting an informal inquiry into the matters discussed above and, subsequently, the Company received and responded to a request from the SEC for the voluntary production of related documents and information. There have been no other requests for documents or information or other developments in connection with this SEC informal inquiry since April 2003.

After disclosure to the IRS in 2003, the IRS commenced audits of the Company’s income tax and employment tax returns for the years 1999-2001. The Company has cooperated in full with this audit and has responded to all requests for information and documents received from the IRS. On February 8, 2006, the Company received a draft of the IRS’s report of its preliminary findings with respect to the employment tax audit. The draft report indicated that the IRS, in addition to imposing liability on the Company for taxes not withheld, intended to assert penalties with respect to both the failure to withhold on non-qualified stock options and the failure to report and withhold on the warrants described above. On

52

April 19, 2006, the Company reached an agreement with the IRS to resolve the employment tax audit.  Pursuant to such agreement the Company paid $28,655,509 to the IRS on April 21, 2006 and on April 28, 2006 the Company paid the IRS $3,080,789, consisting of interest.

B.   Intellectual Property Litigation

As previously reported, on October 28, 2003, a complaint was filed by Yeda Research and Development Company Ltd. (“Yeda”) against ImClone Systems and Aventis Pharmaceuticals, Inc. in the U.S. District Court for the Southern District of New York (03 CV 8484). This action does not seek damages, but rather alleges and seeks that three individuals associated with Yeda should also be named as co-inventors on U.S. Patent No. 6,217,866. On June 7, 2005, Yeda amended its U.S. complaint to seek sole inventorship of the subject patent. On November 4, 2005, the Court denied the Company’s motion for summary judgment with respect to this matter, as filed with the Court on June 24, 2005. Hearings on this matter concluded in July 2006; a determination is forthcoming. The Company is vigorously defending against claims asserted in this action. The Company is unable to predict the outcome of this action at the present time.

As previously reported, on March 25, 2004, an action was filed in the United Kingdom Patent Office entitled Referrer’s Statement requesting transfer of co-ownership and amendment of patent EP (UK) 0 667 165 to add three Yeda employees as inventors. Also on March 25, 2004, a German action entitled Legal Action was filed in the Munich District Court I, Patent Litigation Division, seeking to add three Yeda employees as inventors on patent EP (DE) 0 667 165. The Company was not named as a party in these actions that relate to the European equivalent of U.S. Patent No. 6,217,866 discussed above; accordingly, the Company intervened in the U.K. and German actions. Yeda sought to amend its pleadings in the United Kingdom and Germany to seek sole inventorship. Following hearings, both the U.K. and German courts held that Yeda was not entitled to amend its pleadings. Additionally, on or about March 25, 2005 and March 29, 2005, respectively, Yeda filed legal actions in Austria and France against both Aventis and ImClone Systems seeking full inventorship of EP (AU) 0 667 165 and EP (FR) 0 667 165, as well as payment of legal costs and fees. The Company is vigorously defending against claims asserted in these actions. The Company is unable to predict the outcome of these actions at the present time.

As previously reported, on May 4, 2004, a complaint was filed against the Company by Massachusetts Institute of Technology (“MIT”) and Repligen Corporation (“Repligen”) in the U.S. District Court for the District of Massachusetts (04-10884 RGS). This action alleges that ERBITUX infringes U.S. Patent No. 4,663,281, which is owned by MIT and exclusively licensed to Repligen and that the Company should therefore pay damages. On July 28, 2006, the Court denied the Company’s motion for summary judgment seeking to dismiss all claims on the basis that the patent rights at issue were exhausted as a matter of law and granted MIT and Repligen’s cross motion that their patent rights were not exhausted. The case will now proceed to trial on the merits of the Company’s other defenses. The Company is vigorously defending against claims asserted in this action. The Company is unable to predict the outcome of this action at the present time.

No reserve has been established in the financial statements for any of the Yeda or MIT and Repligen actions because the Company does not believe that such a reserve is required to be established at this time under Statement of Financial Accounting Standards No. 5.

As previously disclosed, the Company is developing a fully human monoclonal antibody, referred to as IMC-11F8, which it intends to commercialize outside the United States and Canada. The Company believes it has the right to do so under its existing development and license agreement with Merck KGaA. However, Merck KGaA had advised the Company that it believed that IMC-11F8 was covered under the development and license agreement with Merck KGaA and that it could therefore have the exclusive rights to market IMC-11F8 outside the United States and Canada and co-exclusive development rights in Japan,

53

for which it would pay the same royalty as it pays for ERBITUX. See “Corporate Collaborations—Collaborations with Merck KGaA”. In agreement with Merck KGaA, the Company submitted this dispute to binding arbitration through an expedited process outside of the provisions of the development and license agreement. Merck KGaA subsequently took the position that the expedited arbitration provision was no longer valid and the Company sued Merck KGaA in federal court in the Southern District of New York to either enforce the arbitration provision previously agreed to or to have the court decide the question of whether IMC-11F8 is or is not covered under the development and license agreement with Merck KGaA. On November 29, 2005, the Court granted the Company’s motion to enforce the expedited arbitration provision previously agreed to, and subsequently appointed a new arbitrator to hear and decide this dispute. On March 31, 2006, the arbitrator decided the matter in favor of the Company, finding that Merck KGaA had no rights to IMC-11F8. That decision is binding and unappealable pursuant to the parties’ arbitration agreement and the parties have subsequently confirmed the arbitration award.

Item 1A.Risk Factors

Supplemental Risks Relating to Intellectual Property

Protecting our proprietary rights is difficult and costly. If we fail to adequately protect or enforce our proprietary rights, we could lose revenue.

Our success depends in large part on our ability to obtain, maintain and enforce our patents. Our ability to commercialize products successfully largely depends on our ability to obtain and maintain patents of sufficient scope to prevent third parties from successfully commercializing similar or competitive products. In the absence of patent protection, competitors may cause a negative impact to our business by developing and marketing substantially equivalent products and technology.

Patent disputes are frequent and can preclude the commercialization of products. We have in the past been, are currently, and may in the future be, involved in material patent litigation, such as the matters discussed under “Part II—Item 1. Legal Proceedings”. Patent litigation is time-consuming and costly in its own right and could subject us to significant liabilities to third parties. In addition, an adverse decision could force us to either obtain third-party licenses at a material cost or cease using the technology or product in dispute.

The existence of patents or other proprietary rights belonging to other parties may lead to our termination of the research and development of a particular product or cause us to obtain third-party licenses at potentially material costs. We believe that we have strong patent protection or the potential for strong patent protection for our product and product candidates. However, it is for the courts and/or other governmental agencies in the U.S. and in other jurisdictions ultimately to determine the strength of that patent protection. We hold patents or licenses to patents relating to murine antibodies as well as patents and licenses relating to the therapeutic use of EGFR antibodies. These patents expire on various dates, the earliest of which is in 2007. Risks related to our patent position with respect to ERBITUX and our product candidates are more fully discussed under “Item 1—Business—Patents and Trademarks” in our 2005 Annual Report on Form 10-K.

54

Several lawsuits have been filed against us, including certain challenges to the inventorship of our licensed patent relating to the therapeutic use of EGFR antibodies, which have resulted, and will likely continue to result, in litigation that is costly to defend and the outcome of which is uncertain and may harm our business.

Litigations or arbitrations to which we are currently, or have been in the past, subjected relate to, among other things, our patent and other intellectual property rights, licensing arrangements with other persons and those other claims more fully described under “Part II—Item 1. Legal Proceedings”, including proceedings currently pending in the U.S. District Court for the Southern District of New York alleging and seeking that three individuals associated with Yeda Research and Development Company Ltd. be named as sole or co-inventors on U.S. Patent No. 6,217,866 relating to the therapeutic use of EGFR antibodies, with related actions pending in the United Kingdom, Germany, France and Austria.

We cannot provide any assurance as to the outcome of these pending lawsuits or arbitrations. Any conclusion of these matters in a manner adverse to us, including any settlement, could have a material adverse effect on our business and operating results. In addition, the costs to us of defending these claims or any other proceedings, even if resolved in our favor, could be substantial. Uncertainties resulting from the initiation and continuation of any litigation or other proceedings could also harm our ability to compete in the marketplace.

Item 2.Unregistered Sales of Equity Securities and Use of Proceeds

Not applicable

Item 3.Defaults upon Senior Securities

Not applicable

Item 4.Submission of Matters to a Vote of Security Holders

Not applicable

Item 5.Other Information

Not applicable

Item 6. Exhibits

Exhibit No.	Description	Incorporated by Reference
3.1	Certificate of Incorporation, as amended through December 31, 1998	D(3.1)
3.2	Amendment dated June 4, 1999 to the Company’s Certificate of Incorporation, as amended	H(3.1A)
3.3	Amendment dated June 12, 2000 to the Company’s Certificate of Incorporation, as amended	K(3.1A)
3.4	Amendment dated August 9, 2002 to the Company’s Certificate of Incorporation, as amended	Q(3.1C)
3.5	Amended and Restated By-Laws of the Company	Z(3.1)
4.1	Rights Agreement dated as of February 15, 2002 between the Company and EquiServe Trust Company, N.A., as Rights Agent, as amended May 4, 2006	JJ(EX-2)

55

4.2	Stockholder Agreement, dated as of September 19, 2001, among Bristol-Myers Squibb Company, Bristol-Myers Squibb Biologics Company and the Company	L(99.2D2)
4.3	Indenture dated as of May 7, 2004 by and between the Company and The Bank of New York, as Trustee and Form of 13¤8% Convertible Notes Due 2024	V(4.5)
4.4	Registration Rights Agreement dated as of May 7, 2004 by and between the Company, as Issuer, and Morgan Stanley & Co., Incorporated and UBS Securities LLC, as the Initial Purchasers	V(4.6)
10.3	1996 Incentive Stock Option Plan, as amended	O(99.1)
10.4	1996 Non-Qualified Stock Option Plan, as amended	O(99.2)
10.5	ImClone Systems Incorporated 1998 Non-Qualified Stock Option Plan, as amended	O(99.2)
10.6	ImClone Systems Incorporated 2002 Stock Option Plan	Q(99.8)
10.7	ImClone Systems Incorporated 1998 Employee Stock Purchase Plan	I(99.4)
10.8	Option Agreement, dated as of September 1, 1998, between the Company and Ron Martell	F(99.3)
10.10	License Agreement between the Company and the Regents of the University of California dated April 9, 1993	B(10.48)
10.12	License Agreement between the Company and Rhone-Poulenc Rorer dated June 13, 1994	C(10.56)
10.13	Development and License Agreement between the Company and Merck KGaA dated December 14, 1998	E(10.70)
10.14	Lease Agreement dated as of December 15, 1998 for the Company’s premises at 180 Varick Street, New York, New York	G(10.69)
10.15	Amendment dated March 2, 1999 to Development and License Agreement between the Company and Merck KGaA	G(10.71)
10.16	Acquisition Agreement dated as of September 19, 2001, among the Company, Bristol-Myers Squibb Company and Bristol-Myers Squibb Biologics Company	L(99.D1)
10.17	Development, Promotion, Distribution and Supply Agreement, dated as of September 19, 2001, among the Company, Bristol-Myers Squibb Company and E.R. Squibb & Sons, L.L.C	L(99.D3)
10.20	Employment Agreement, dated as of March 19, 2004, between the Company and Daniel S. Lynch	U(10.1)
10.21	Agreement of Sublease dated October 5, 2001, by and between 325 Spring Street LLC and the Company	O(10.86)
10.22	Promissory Note in the principal amount of $10,000,000, dated October 5, 2001, executed by 325 Spring Street LLC in favor of the Company	O(10.86.1)
10.23	Amendment No. 1 to Development, Promotion, Distribution and Supply Agreement, dated as of March 5, 2002, among the Company, Bristol-Myers Squibb Company and E.R. Squibb & Sons, L.L.C	N(99.2)
10.24	Amendment, dated as of August 16, 2001 to the Development and License Agreement between the Company and Merck KGaA	P (10.88)
10.25	Agreement of Sale and Purchase between Building Associates, LP and ImClone Systems Incorporated pertaining to 33 Chubb Way, Branchburg, New Jersey executed as of March 1, 2002	Q(10.92)

56

10.26	Target Price Contract, dated as of July 15, 2002, between ImClone Systems Incorporated and Kvaerner Process, a division of Kvaerner U.S. Inc., for the Architectural, Engineering, Procurement Assistance, Construction Management and Validation of a Commercial Manufacturing Project in Branchburg, New Jersey	R(10.930)
10.27	Modifications Agreement dated as of December 15, 2000 by an between 180 Varick Street Corporation and the Company	S(10.94)
10.28	Amendment Number 4 to the Company’s lease at 180 Varick Street dated August 13, 2004 by and between 180 Varick Street Corporation and the Company	V(10.28)
10.29	ImClone Systems Incorporated Annual Incentive Plan	T(A.C)
10.30	Supply Agreement between the Company and Lonza Biologics PLC dated March 17, 2005	Y(10.30)
10.31	ImClone Systems Incorporated Senior Executive Severance Plan	W(10.29)
10.32	ImClone Systems Incorporated Change in Control Plan, as amended	FF (10.32)
10.34	Terms of inducement stock option grants to Drs. Philip Frost and Eric Rowinsky on March 1, 2005 and February 21, 2005, respectively, as approved by the Compensation Committee of Board of Directors	AA
10.35	Collaboration and License Agreement between the Company and UCB S.A. dated August 15, 2005. Confidential Treatment has been requested for a portion of this Exhibit	CC (10.35)
10.36	Approval by Board of Directors of certain compensation related matters and Company stock repurchase program	BB
10.37	ImClone Systems Incorporated 2005 Inducement Stock Option Plan	DD(10.1)
10.38	Terms of accelerated Company stock options and form of lock-up agreement	EE(10.1)
10.39	ImClone Systems Incorporated 2006-2008 Retention Plan	GG(10.1)
10.40	ImClone Systems Incorporated Transition Severance Plan	FF(10.40)
10.41	Approval by the Compensation Committee of Board of Directors of performance criteria for executive officer cash bonus awards under the Company’s Annual Incentive Plan for the year ended December 31, 2006, together with maximum permitted bonuses under the plan	HH
10.42	Letter Agreement, dated March 21, 2006, by and between Joseph L. Fischer and ImClone Systems Incorporated	II(10.42)
31.1*	Certification of the Company’s Interim Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*	Certification of the Company’s Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32*	Certification of the Company’s Interim Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

*	Filed herewith.
(B)	Previously filed with the Commission; incorporated by reference to the Company’s Annual Report on Form 10-K, File No. 0-19612, for the fiscal year ended December 31, 1993. Confidential Treatment was granted for a portion of this Exhibit.
(C)	Previously filed with the Commission; incorporated by reference to the Company’s Annual Report on Form 10-K, File No. 0-19612, for the fiscal year ended December 31, 1994.

57

(D)	Previously filed with the Commission; incorporated by reference to the Company’s Quarterly Report on Form 10-Q, File No. 0-19612, for the quarter ended June 30, 1997.
(E)	Previously filed with the Commission; incorporated by reference to the Company’s Registration Statement on Form S-3, File No. 333-67335. Confidential treatment was granted for a portion of this Exhibit.
(F)	Previously filed with the Commission; incorporated by reference to the Company’s Registration Statement on Form S-8, File No. 333-64827.
(G)	Previously filed with the Commission; incorporated by reference to the Company’s Annual Report on Form 10-K, File No. 0-19612, for the fiscal year ended December 31, 1998.
(H)	Previously filed with the Commission; incorporated by reference to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 1999.
(I)	Previously filed with the Commission; incorporated by reference to the Company’s Annual Report on Form 10-K for the year ended December 31, 1999.
(K)	Previously filed with the Commission; incorporated by reference to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2000.
(L)	Previously filed with the Commission; incorporated by reference to the Company’s Schedule 14D-9 filed on September 28, 2001.
(N)	Previously filed with the Commission; incorporated by reference to the Company’s Current Report on Form 8-K dated March 6, 2002.
(O)	Previously filed with the Commission; incorporated by reference to the Company’s Annual Report on Form 10-K, for the year ended December 31, 2001.
(P)	Previously filed with the Commission; incorporated by reference to the Company’s Annual Report on Form 10-K, for the year ended December 31, 2001, and Confidential Treatment has been requested for a portion of this exhibit.
(Q)	Previously filed with the Commission; incorporated by reference to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2002.
(R)	Previously filed with the Commission; incorporated by reference to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2002.
(S)	Previously filed with the Commission; incorporated by reference to the Company’s Annual Report on Form 10-K, for the year ended December 31, 2002.
(T)	Previously filed with the Commission; incorporated by reference to the Company’s Proxy Statement for its 2003 Annual Meeting of Shareholders, filed August 21, 2003, as appendix C.
(U)	Previously filed with the Commission; incorporated by reference to the Company’s Current Report on Form 8-K dated March 19, 2004.
(V)	Previously filed with the Commission; incorporated by reference to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2004.
(W)	Previously filed with the Commission; incorporated by reference to the Company’s Annual Report on Form 10-K for the year ended December 31, 2004.
(Y)	Previously filed with the Commission; incorporated by reference to the Quarterly Report on Form 10-Q for the quarter ended March 31, 2005.
(Z)	Previously filed with the Commission; incorporated by reference to the Company’s Current Report on Form 8-K dated June 21, 2005.
(AA)	Previously filed with the Commission; incorporated by reference to the Company’s Current Report on Form 8-K dated July 15, 2005.
(BB)	Previously filed with the Commission; incorporated by reference to the Company’s Current Report on Form 8-K dated September 19, 2005.
(CC)	Previously filed with the Commission, incorporated by reference to the Quarterly Report on Form 10-Q for the quarter ended September 30, 2005.
(DD)	Previously filed with the Commission; incorporated by reference to the Company’s Current Report on Form 8-K dated October 21, 2005.

58

(EE)	Previously filed with the Commission, incorporated by reference to the Company’s Current Report on Form 8-K dated December 21, 2005.
(FF)	Previously filed with the Commission; incorporated by reference to the Company’s Annual Report on Form 10-K for the year ended December 31, 2005.
(GG)	Previously filed with the Commission; incorporated by reference to the Company’s Current Report on Form 8-K dated January 23, 2006.
(HH)	Previously filed with the Commission, incorporated by reference to the Company’s Current Report on Form 8-K dated March 22, 2006.
(II)	Previously filed with the Commission, incorporated by reference to the Company’s Current Report on Form 10-K/A dated May 1, 2006.
(JJ)	Previously filed with the Commission, incorporated by reference to The Company’s Current Report on Form 8-A/A dated May 4, 2006.

59

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	IMCLONE SYSTEMS INCORPORATED (Registrant)
	By:	/s/ JOSEPH L.FISCHER
		Joseph L. Fischer
		Interim Chief Executive Officer
Date: August 4, 2006
	By:	/s/ MICHAEL J. HOWERTON
		Michael J. Howerton
		Chief Financial Officer
Date: August 4, 2006

60

EX-31.1

EXHIBIT 31.1

CERTIFICATION

I, Joseph L. Fischer, Interim Chief Executive Officer of ImClone Systems Incorporated, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q for the quarter ended June 30, 2006 of ImClone Systems Incorporated;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)   Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the Audit Committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)   Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	/s/ JOSEPH L. FISCHER
	Joseph L. Fischer
	Interim Chief Executive Officer
Date: August 4, 2006

EX-31.2

EXHIBIT 31.2

CERTIFICATION

I, Michael J. Howerton, Chief Financial Officer of ImClone Systems Incorporated, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q for the quarter ended June 30, 2006 of ImClone Systems Incorporated;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)   Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)   Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the Audit Committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)   Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	/s/ MICHAEL J. HOWERTON
	Michael J. Howerton
	Chief Financial Officer
Date: August 4, 2006

EX-32

EXHIBIT 32

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of ImClone Systems Incorporated (the “Company”) for the quarter ended June 30, 2006, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Joseph L. Fischer, Interim Chief Executive Officer of the Company, and Michael J. Howerton, Chief Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	/s/ / JOSEPH L. FISCHER
	Joseph L. Fischer
	Interim Chief Executive Officer
August 4, 2006
	/s/ MICHAEL J. HOWERTON
	Michael J. Howerton
	Chief Financial Officer
August 4, 2006

This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.